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I. Zusammenfassung 
Der Name paroxysmale nächtliche Hämoglobinurie (PNH) steht für eine erworbene 
Erkrankung, bei der die Erythrozyten innerhalb der Blutgefäße lysieren (intravasale 
Hämolyse). Aufgrund einer erworbenen Veränderung in ihrem Genom weist ein Teil der 
Blutzellen bei Patienten mit PNH einen Defekt einer Gruppe von Oberflächenproteinen auf, 
die nicht konventionell, sondern über ein besonderes Ankermolekül (GPI-Anker) mit der 
Zellmembran verbunden sind. Zwei dieser Moleküle regulieren das Komplement und sind die 
einzigen Komplement-Regulatoren auf den Erythrozyten. Wenn die Komplementkaskade 
nicht an der Membran reguliert wird, kommt es zu einem erheblichen Zellschaden bis hin zur 
Lyse der Zelle. Das Auftreten der GPI-defizienten Zellen im Blut der PNH-Patienten beruht 
auf einer Vermehrung eines oder weniger einzelner Zellklone mit der oben beschriebenen 
Veränderung in ihrer Erbsubstanz im Knochenmark (klonale Expansion). Der Mechanismus 
der klonalen Expansion ist bis zum heutigen Tag nicht geklärt. Eine Hypothese postuliert 
einen Selektionsmechanismus, durch den die normalen Zellen erkannt und eliminiert werden. 
Es bleiben die GPI-defizienten Zellen übrig, und das Knochenmark und das periphere Blut 
werden von den GPI-defizienten Zellen dominiert. Die Identifizierung solcher autoreaktiven 
Antikörper erfolgte mittels SEREX (Serological analysis of antigens by recombinant 
expression cloning). Dazu wurde eine humane fötale Leber-cDNA-Expressionsbank mit 10 
Seren von PNH-Patienten, 5 aplastischer Anämie, 10 myelodysplastischem Syndrom (MDS) 
und 20 gesunden Individuen auf immunreaktive Klone untersucht. Dabei konnten insgesamt 
zwei reaktive Klone identifiziert werden, welche in CD34+ Zellen sowohl aus gesundem 
Knochenmark als auch aus PNH Knochenmark auf gleiche Weise exprimiert werden. Bei 
3/10 PNH-Patienten wurde eine Antikörper-Reaktion gegen M-Phase Phosphoprotein 1 
(MPHOSPH 1) und bei 4/10 PNH-Patienten eine Antikörper-Reaktion gegen Desmoplakin 
identifiziert. Weder mit Seren von Patienten mit aplastischer Anämie noch mit MDS Seren 
waren Reaktionen zu beobachten. Wir fanden auch eine Antikörper-Reaktion in einem der 20 
gesunden Probanden gegen Desmoplakin, aber mit einem viel niedrigen Titer als bei PNH-
Patienten (102 zu 105). Kein Unterschied konnte festgestellt werden bei den DNA-Sequenzen 
beider Klone aus PNH CD34+ Zellen und denen aus gesunden CD34+ Zellen. Aus den 
Ergebnissen lässt sich schließen, dass MPHOSPH1 und Desmoplakin zwei Autoantigene sind, 
die vom Immunsystem der PNH-Patienten erkannt werden. Diese Ergebnisse können zu 
einem besseren Verständnis der Pathophysiologie der Krankheit beitragen.  
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II. Summary 
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a consequence of a non-malignant clonal 
expansion of hematopoietic stem cells with a somatic mutation of the PIG-A gene. Mutations 
in the PIG-A gene lead to a deficiency of glycosyl phosphatidyl inositol–anchored proteins 
(GPI-APs). This deficiency leads to a complete absence of complement regulating proteins on 
the surface of red blood cells and thus explains the intravascular hemolysis of PNH. However, 
this mechanism does not account for the clonal expansion of GPI-AP-deficient cells. Since the 
PIG-A mutation does not confer to an intrinsic growth advantage within the bone marrow; 
this suggests a second event to be responsible for the clonal expansion of mutant cells. A 
hypothesis assumes a defect in the immune system leading to an immune attack directed 
against specific antigens, which have yet to be identified. In order to identify the auto-
antigens in PNH patients, a human fetal liver cDNA library was screened for hematopoietic 
stem/progenitor cells antigens using the SEREX (Serological analysis of antigens by 
recombinant expression cloning) approach. For the screening 10 PNH sera, 5 aplastic Anemia, 
10 Myelodysplastic syndrome (MDS) and 20 healthy volunteers sera were used. Two antigens 
were identified that are constitutively expressed in CD34+ cells from both healthy and PNH 
bone marrow. Three of 10 PNH patients were identified to exhibit an antibody response 
against M-phase phosphoprotein 1 (MPHOSPH1) and four of 10 PNH patients were identified 
with an antibody response against desmoplakin. A weak serological response in one of 20 
healthy volunteers against desmoplakin was detected, however at a much lower titer than in 
PNH patients (102 in normal serum VS 105 in PNH sera). No response to MPHOSPH1 or 
desmoplakin was detected in 5 patients with aplastic anemia or the 10 patients with MDS. 
Moreover, no difference between the cDNA sequences of the clones (MPHOSPH1 and 
desmoplakin) isolated from PNH CD34+ cells and from healthy CD34+ cells were identified.  
From the results, it can be concluded that MPHOSPH1 and desmoplakin are two auto-
antigens that are recognized by the immune system of PNH patients. The analysis of the 
mechanisms underlying this auto-immunity might contribute to a better understanding of the 
clonal expansion associated with this disease. 
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III. Glossary 
 
AA Aplastic anemia 
APC Antigen presenting cell 
BCIP 5-bromo-4-chloro-3-indoly-phosphate 
CDR Commonly deleted region 
cGMP Cyclic guanine mono-phosphate 
CMML Chronic myelomonocytic leukemia 
DAF Decay accelerating factor 
dNTPs deoxynucleotides triphosphates 
DSP Desmoplakin 
FAB French-American-British 
GPI Glycosyl phosphatidyl inositol 
HMGA2 High mobility group AT-hook protein 2 
IPSS International Prognostic Scoring System 
IPTG isopropyl-1-thio-β-D-galactopyranoside 
IS Immunosuppressive therapy 
LGLL large granular lymphocyte leukemia 
MAC Membrane attack complex 
MDS Myelodysplastic syndromes 
MIRL Membrane inhibitor of reactive lysis 
MPHOSPH1 or MPP1 M- Phase phosphoprotein 
MPS Myeloproliferative disease 
NBT Nitroblue tetrazolium 
NK Natural Killer 
MOPS 3-(N-Morpholino)-propanesulfonic acid 
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NOS Nitric oxide synthesis 
PIG-A phosphatidylinositol glycan anchor biosynthesis, class A 
PNH Paroxysmal Nocturnal Hemoglobinuria 
RA Refractory anemia 
RARS Refractory anemia with ringed sideroblasts 
RAEB refractory anemia with excess blasts  
RAEB-T Refractory anemia with excess blasts in transformation 
SEREX Serological analysis of antigens by recombinant expression 
cloning 
TCR T cell receptor 
TNF-α Tumor necrosis factor-alpha 
WHO World Health Organization 
WT1 Wilms’ tumor-1 protein 
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IV-Introduction 
1. Paroxysmal Nocturnal Hemoglobinuria (PNH) 
1.1. Definition 
Paroxysmal Nocturnal Hemoglobinuria (PNH) is an acquired disorder of hematopoietic stem 
cells; its estimated prevalence is about 1/105 people. Three recent large clinical studies on 
patients with PNH indicated that it may occur at any age from children as young as 8 months 
to adults up to 82 years of age and that it occurs most frequently in adults of age 30–50. The 
clinical manifestation of PNH is complex involving primarily three sets of symptoms: 
hemolysis with acute exacerbation (Figure 1), cytopenia of variable severity, and a tendency 
for abnormal thrombosis (Nishimura et al, 1999a). 
 
Figure 1:Urine samples from a patient with PNH. Urine sampled at 7 am is dark, containing a large 
amount of free hemoglobin, which leaks out of PNH red cells as they burst. The urine generally clears 
during the day. 
1.2. Etiology 
1.2.1. Glycosyl phosphatidyl inositol-linked antigens and PNH  
The fact that a variety of proteins attach to the cell membrane by glycolipid structure is well 
known since 1980s. These proteins are attached to the cell membrane with the same basic 
backbone consisting of a phosphatidyl inositol, a single glucosamine, three mannoses and an 
ethanolamine. The glycosyl phosphatidyl inositol (GPI) structure is depicted in (Figure 2).  
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Figure 2: Structure of GPI anchor. GPI anchor consists of a phosphatidyl inositol, a single 
glucosamine, three mannoses and an ethanolamine—a Glycosyl phosphatidyl inositol.  
1.2.1.1. GPI-anchor biosynthesis  
PIG genes are involved in the biosynthesis of the GPI-anchor and its binding to proteins, 
which takes place in the endoplasmic reticulum ER (Figure 3). GPI-linked proteins can be 
released by specific phospholipases, for example GPI-PLS and GPI-PLD (Tashima et al, 
2006). In trypanosomes, GPI-PLC-controlled release of the variant specific glycoprotein, the 
main coat protein, enables the parasite to evade the host immune response. However, the 
functional role of GPI-PLC and GPI-PLD in human tissues remains elusive. Good lateral 
mobility, which is another characteristic of GPI-anchor, is likely to be relevant for many GPI-
linked proteins that require the clustering of GPI-anchor molecules in the association with 
microdomains, or “rafts”, enriched in glycophospholipids and cholesterol. The association 
with microdomains contributes to the specific surface distribution of GPI-linked proteins and 
aids in the recruitment of accessory molecules for the cell signaling (Horejsi et al, 1998).  
 
12 
 
 
 
Figure 3: GPI-anchor biosynthesis. Steps (1-8) are the assembling of GPI-anchor precursors by 
adding sequential of components to phosphatidyl inositol. (Steps 9 and 10) GPI-anchor precursors 
linked to the carboxyl terminus of the protein to form GPI-anchored protein. (Modified according to 
Takeda and Kinoshita, 1995) 
 
The PIG-A gene is located on the short (p) arm of the X chromosome at position 22.1, from 
base pair 15,247,500 to base pair 15,263,565 (Figure 4). The PIG-A gene is approximately 17 
kilo bases (kb) long and has six exons. Exon1 is non-coding, and exon 2 accommodates 
almost half of the PIG-A gene-coding region (Iida et al, 1994b). Exon 5 contains sequences 
that have homology to the Glc-NAc-transferase of Salmonella typhimurium and 
glycosyltransferases in plants and thus might be the binding site of UDPGlcNAc (Bessler et 
al, 1994b). Exon 6 contains the trans-membrane domain of PIG-A. The PIG-A cDNA consists 
of 3589 base pairs (bp) with an open reading frame of 1452 bp encoding a putative protein of 
484 amino acids. The PIG-A gene maps to the short arm of the X chromosome at X p22.1. A 
non-functional processed pseudo gene was mapped to 12 p21.  
1.2.1.2. PIG-A gene mutations 
A single mutation can cause the loss of GPI-linked proteins on both male and female somatic 
cells. Thus, in males the inactivation of one PIG-A allele is sufficient to cause the loss of 
GPI-linked proteins on the cell surface. In females, the inactivation of PIG-A allele when it is 
on the active X  chromosome will lead to the loss of GPI-linked proteins on the cell surface 
(due to random X-inactivation this is expected to occur in about half of the cells). Therefore, 
in both male and female cells, a single mutation (1 hit) can be sufficient to inactivate PIG-A 
protein function resulting in the loss of GPI linked proteins on the cell surface. All other genes 
involved in the GPI-anchor biosynthesis are autosomal. Therefore, the loss of GPI-anchored 
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proteins would require two separate mutations on the two different alleles, an event that is 
extremely unlikely to occur. 
 
Figure 4: Location of PIG-A gene on chromosome X. The PIGA gene is located on the short arm of 
the X chromosome at the position 22.1 from base pair 15,337,577 to base pair 15,353,659 of the 
chromosome. 
To date, more than 180 mutations are known to be found in GPI-deficient blood cells from 
patients with PNH (Bessler & Hiken, 2008). The majority of PIG-A gene mutations are frame 
shift mutations that predict an inactive PIG-A protein and a loss of glycosyltransferase 
activity. The mutations are distributed over the entire coding region with no obvious 
clustering. Only 16 out of 174 mutations were reported to be present in more than one PNH 
patient (Nishimura et al, 1999b). There is some clustering of missense mutations over the 
coding region of exon 2. Some of these missense mutations were shown to cause only a 
partial deficiency in GPI-linked proteins on the cell surface. This indicates that the mutant 
glycosyltransferase has some residual activity (Bessler et al, 1994c).  
1.2.2. Intravascular Hemolysis in PNH 
The work of Ham (Ham et al, 1948) in the 1930s first revealed that the hemolysis in PNH was 
due to the effect of a serum factor on abnormal PNH red cells. Rosse et al (Rosse & Ware, 
1995) proceeded to show that this factor was the complement, that when activated led to the 
intravascular hemolysis of PNH red cells. The characteristic symptoms of PNH can be 
attributed to the intense intravascular hemolysis and the resulting free plasma hemoglobin. 
This appears to be due to the absorption of nitric oxide by free hemoglobin and since nitric 
oxide is critical for smooth muscle function. During intravascular hemolysis, hemoglobin is 
released into the plasma where it is normally cleared by the hemoglobin’s scavengers: 
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haptoglobin, CD163, and hemopexin. Haptoglobin-hemoglobin complexes bind to CD163 on 
the surface of macrophages/monocytes initiating endocytosis and degradation of the complex. 
Hemoglobin also releases ferric heme on oxidation, which is bound by hemopexin and 
degraded by hepatocytes in the liver (Rother et al, 2005). Excessive hemolysis saturates and 
depletes these hemoglobin removal systems and leads to a buildup of hemoglobin and heme 
in the plasma. Plasma hemoglobin and heme mediate direct pro-inflammatory, proliferative, 
and pro-oxidant effects on vessel endothelial cells. NO is normally generated from L-arginine 
in vessel endothelial cells by the enzyme nitric oxide synthesis (NOS). NO maintains smooth 
muscle relaxation and inhibits platelet activation and aggregation, thereby regulating vessel 
tone and promoting organ system homeostasis. During intravascular hemolysis, NO 
availability can be severely limited by its reaction with oxy-hemoglobin (NO scavenging) and 
by the breakdown of the substrate for NO synthesis, L-arginine, by the red cell enzyme 
arginase, despite elevated levels of NOS (decreased NO synthesis). NO depletion results in 
decreased activation of guanylate cyclase, an enzyme required for the generation of cyclic 
guanine mono-phosphate (cGMP). Decreased cGMP levels disrupt regulation of smooth 
muscle tone resulting in dystonias, including systemic and pulmonary hypertension, erectile 
dysfunction, dysphagia, and abdominal pain. Decreased cGMP levels through the depletion of 
NO can also lead to platelet activation and aggregation, promoting clot formation (Figure 5). 
 
Figure 5: Pathobiological effects of cell-free plasma hemoglobin and nitric oxide (NO) 
depletion during intravascular hemolysis. (Rother et al, 2005). 
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Figure 6: Regulation of complement activity. Binding of poly C9 to the C5b678 complex leads to the 
formation of membrane attack complex (MAC), the binding could be inhibited by CD59. (Modified, from 
Department of Biology, Davidson College, 2005) 
The functions of the GPI-linked antigens are divergent. At least two are important in the 
control of complement: Decay accelerating factor (DAF or CD55), which controls the early 
part of the complement cascade by regulating the activity of the C3 and C5 convertases. Thus, 
CD55 deficiency initially appeared to explain the sensitivity of PNH red cells to complement. 
However, the observation that individuals with inherited CD55 deficiency (Inab-phenotype) 
did not suffer from hemolysis proved that deficiency of CD55 does not cause the hemolysis in 
PNH. The second protein is Membrane inhibitor of reactive lysis (MIRL or CD59) which is 
GPI-linked protein and it was identified in 1989. CD59 inhibits terminal complement by 
preventing the incorporation of C9 onto C5b-8 (Figure 6 and 7) and therefore preventing the 
formation of the membrane attack complex (MAC). In 1990, an individual with inherited 
isolated deficiency of CD59 was described with many features similar to classic PNH, such as 
intravascular hemolysis with hemoglobinuria and thrombosis of the cerebral veins (Iida et al, 
1994a). Therefore, CD59 deficiency is the abnormality that is responsible for the hemolysis 
and thrombosis typical of PNH.  
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Figure 7: Complement mediated lysis of GPI-anchor deficient erythrocytes in PNH. (A) by 
normal blood cells: CD55 inhibits the formation or destabilizes the C3 confertase and CD59 protects 
the membrane from attack by the C5-C9 complex. (B) In PNH: the membrane attack complex can be 
formed because of the deficiency of both CD55 and CD59; the complex ruptures the membrane and 
the cell lysis. (Modified according to Lyakisheva and Schubert 2002). 
 
Figure 8: Effect of CD59 on T cell-APC interactions. The interaction of T cells with a specific 
receptor of an APC results in an inhibitory signal between the two cells, which reduces the strength of 
positive signals delivered through the TCR. (Modified, from the Department of Biology, Davidson 
College, 2005) 
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CD59 influences the outcome of a T cell response to a given antigen. Longhi et al (Longhi et 
al, 2006) have demonstrated in 2006 that direct interaction between CD59 on a T cell and a 
specific receptor on an antigen presenting cell (APC) results in an inhibitory signal being 
transmitted to both the T cell and the APC. Due to this inhibitory signal, down-modulation of 
APC activity and consequently T cell activity results as well. They also postulated that CD59 
on T cells may reduce the strength of the positive signal transduction pathway delivered 
through the T cell receptor (TCR). A diagram for CD59 interacting with T cells and APCs is 
shown in (Figure 8). 
1.2.3 Relative growth advantage of the PNH clone 
PNH is a disorder in which an abnormal clone or small number of clones expand to replace 
almost the entire hematopoietic stem cell pool, but these clones do not have any “malignant” 
tendency in that they appear to be regulated in a normal manner with no tendency to 
metastasize beyond the normal hematopoietic compartment. Although GPI-deficient cells 
with PIG-A mutations occur very frequently at low levels in normal individuals they do not 
expand in competition with the normal hematopoietic cells. Hillmen and Dacie (Hillmen et al, 
1995) first proposed that in order to develop PNH two things are required: first, the 
occurrence of a GPI-deficient clone arising in a multipotent hematopoietic stem cell; second, 
a second event that favors the expansion of the PNH clone over the residual normal 
hematopoiesis—a relative growth advantage for the PNH cells. The clue to this second event 
is the close relationship between aplastic anemia and PNH. It appears that normal 
hematopoiesis is suppressed by the immune system, presumably either directly or indirectly 
through one or more GPI-linked antigens, and therefore this attack spares the GPI-deficient 
PNH clone. Thus, in an environment where there is intense pressure for hematopoiesis (for 
example in aplastic anemia), the PNH clone is driven to produce mature hematopoietic cells 
and expands to fill the void left by the aplastic process. The exact mechanism for the relative 
growth advantage of PNH cells remains unclear. In 2006, Inoue et al (Inoue et al, 2006a) 
reported 2 patients with PNH whose PIGA-mutant cells (and not normal cells) had an acquired 
rearrangement of chromosome 12. In both cases, the chromosome had a break within the 3' 
untranslated region of HMGA2, the architectural transcription factor gene deregulated in many 
benign mesenchymal tumors, which caused ectopic expression of HMGA2 in the bone 
marrow. These observations suggest that aberrant HMGA2 expression, in concert with mutant 
PIGA, accounts for clonal hematopoiesis in both patients and suggest the concept of PNH as a 
benign tumor of the bone marrow. 
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1.2.4. Clonal selectivity in PNH 
The study of Horikawa et al (Horikawa et al, 1997) confirmed that the blood cells obtained 
from patients with PNH are less susceptible to both spontaneous and ligand induced apoptosis 
in vitro than those from healthy volunteers. The resistance to apoptosis was evident in the 
granulocytes but unclear in the lymphocytes. 
The PIG-A gene is responsible for the membrane defect of PNH cells and it might play an 
important role in the resistance to apoptosis, although the study of Horikawa et al showed no 
correlation between resistance to apoptosis and the proportion of cells with PNH phenotype. 
In 2002 Nagakura et al (Nagakura et al, 2002a) found that leukemic cells with PIG-A 
mutations ( GPI - cells) are less susceptible than the control counterparts ( GPI +cells) to kill 
by natural Killer ( NK) cells in vitro, which supports a selective survival advantage theory. 
They also suggested that NK cells might spare PIG-A mutant cells from killing in vivo as well 
as in vitro. The study showed also that neither CD55 nor CD59 were the target antigens for 
the NK.  
2. Myelodysplastic syndromes (MDS) 
2.1. Definition 
Myelodysplastic syndromes (MDS) are a group of acquired neoplastic disorders of 
multipotent hematopoietic stem cells characterized by increasing bone marrow failure with 
quantitative and qualitative abnormalities of all three cell lines. A hallmark of the disease is 
an active but ineffective hematopoiesis leading to pancytopenia. MDS were recognized for 
more than 50 years and were called preleukemia, smoldering leukemia, oligoblastic leukemia, 
and refractory anemia. There is a tendency to progress to AML, although death can also occur 
before this develops (Heaney & Golde, 1999). The term MDS reflects the presence of 
dysplasia in bone marrow and peripheral blood. Dysplasia may reflect disordered maturation 
and fragmentation of the nuclear structures, both of which are signs of increased apoptosis 
(Kouides & Bennett, 1997).  
MDS were probably first described in 1900 by Leube as "leukanaemie", that at the time were 
thought to have an infectious etiology. After that, all patients who developed acute leukemia 
after having macrocytic anemia were given a diagnosis of “pre-leukemia” until the 1970s, 
when it was realized that many such patients never developed acute leukemia, but instead died 
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of complications from the cytopenias. The “pre-leukemia” terminology faded away, and the 
term “myelodysplastic syndrome” became widely accepted. Signs and symptoms of anemia, 
accompanied by infectious or bleeding complications, predominate in MDS, with some 
patients having systemic symptoms or features of autoimmunity, perhaps indicative of the 
pathogenesis of their disease (Nimer, 2008). 
2.2. Classification of MDS 
The first French-American-British (FAB) Cooperative Group meeting identified two broad 
categories of “dysmyelopoietic syndrome”. In 1982, they expanded their classification to the 
modern five subcategories of MDS: Refractory anemia (RA), refractory anemia with ringed 
sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory anemia with 
excess blasts in transformation (RAEB-T) and chronic myelomonocytic leukemia (CMML) 
(Bennett et al, 1982). Despite its obvious limitations, the FAB classification has remained the 
standard for more than two decades. Nonetheless, it was substituted by the World Health 
Organization (WHO) classification. The WHO classification incorporates many of the 
concepts and definitions of the FAB system, but it also recognizes recently published data to 
refine the definition of some subtypes and thus to improve their clinical relevance (Vardiman 
et al, 2002b). The most important difference between the WHO and FAB classifications is the 
lowering of the blast threshold for the diagnosis of AML from 30% to 20% blasts in the blood 
or bone marrow. As a result, the FAB category RAEBT is eliminated from the WHO 
classification (Greenberg et al, 1997c). Most recently, the WHO has evolved a new 
classification scheme (2008) which is based more on genetic findings (Table 1). However, 
morphology of the cells in the peripheral blood, bone marrow aspirate, and bone marrow 
biopsy is still the screening test used in order to decide which classification is best and which 
cytogenetic aberrations may be related. 
Other changes include a refinement of the definitions for the lower-grade lesions, RA, and 
RARS, and the addition of a new category, refractory cytopenia with multi-lineage dysplasia 
(RCMD). Two subtypes of RAEB, RAEB-1 with 5% to 9% marrow blasts and RAEB-2 with 
10% to 19% marrow blasts, are also recognized. They take into account data published by the 
International MDS Risk Analysis Workshop that patients with 10% or more blasts in the bone 
marrow have a worse clinical outcome than do those with fewer blasts. The WHO 
classification also recognizes the “5q  syndrome” as a unique, narrowly defined entity. 
Lastly, because of the controversy as to whether chronic myelomonocytic leukemia (CMML) 
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is a myelodysplastic or a myeloproliferative disease, this disorder was placed in a newly 
created disease group, MDS/MPD. The International Prognostic Scoring System (IPSS) relies 
on the primacy of the number of cytopenias, cytogenetic profile, and the percentage blasts in 
the bone marrow into one of four prognostic categories: low risk, intermediate 1 risk, 
intermediate 2 risk, and high risk (Table 2). 
Table 1. WHO classification of MDS (new and old system). 
WHO classification 
old system 
WHO classification 
new system 
Refractory anemia (RA) Refractory cytopenia with unilineage dysplasia (Refractory anemia, 
Refractory neutropenia, and Refractory thrombocytopenia) 
Refractory anemia with 
ringed sideroblasts 
(RARS) 
Refractory anemia with ring sideroblasts (RARS) 
 
Refractory anemia with ring sideroblasts - thrombocytosis (RARS-t) 
(provisional entity) which is in essence a 
myelodysplastic/myeloproliferative disorder and usually has a JAK2 
mutation (janus kinase) - New WHO classification 2008 
 Refractory cytopenia with multilineage dysplasia (RCMD) includes 
the subset Refractory cytopenia with multilineage dysplasia and ring 
sideroblasts (RCMD-RS). RCMD includes patients with pathological 
changes not restricted to red cells (i.e., prominent white cell precursor 
and platelet precursor (megakaryocyte) dysplasia. 
Refractory anemia with 
excess blasts (RAEB) 
Refractory anemia with excess blasts I and II. RAEB was divided into 
*RAEB-I (5-9% blasts) and RAEB-II (10-19%) blasts, which has a 
poorer prognosis than RAEB-I. Auer rods may be seen in RAEB-II 
which may be difficult to distinguish from acute myeloid leukemia. 
Refractory anemia with 
excess blasts in 
transformation (RAEB-
T) 
The category of RAEB-T was eliminated; such patients are now 
considered to have acute leukemia. 5q- syndrome, typically seen in 
older women with normal or high platelet counts and isolated 
deletions of the long arm of chromosome 5 in bone marrow cells, was 
added to the classification. 
Chronic 
myelomonocytic 
leukemia (CMML) 
CMML was removed from the myelodysplastic syndromes and put in 
a new category of myelodysplastic-myeloproliferative overlap 
syndromes. 
 5q- syndrome 
 Myelodysplasia unclassifiable (seen in those cases of megakaryocyte 
dysplasia with fibrosis and others) 
 Refractory cytopenia of childhood (dysplasia in childhood) - New 
WHO classification 2008 
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Table 2. International Prognostic Scoring System IPSS (Greenberg et al, 1997a) 
 Risk group   Total score   Median survival, y   Time for 25% to progress to AML, y  
 Low   0   5.7   9.4  
 Intermediate-1   0.5-1.0   3.5   3.3  
 Intermediate-2   1.5-2.0   1.2   1.1  
 High    2.5   0.4   0.2  
 
2.3. Causes & Risk Factors 
Most cases of MDS have no known cause, but some factors were determined to increase the 
risk. Advancing age is perhaps the most common risk factor, since it rarely occurs in people 
under the age of 60. Other risk factors include smoking, long-term exposure to benzene 
and prior treatment with chemotherapy or radiation (West et al, 1995).  
2.4. Pathophysiology of MDS 
Both MDS and myeloproliferative diseases can be thought of as preleukemic disorders. AML 
is characterized by a block in differentiation, but also the ongoing ability of the myeloblasts 
(and leukemic stem cells) to survive and proliferate. In contrast, MDSs have impaired 
differentiation, making it likely that a second mutation, which allows the blasts to survive and 
proliferate, is needed for the disease to progress to AML. Likewise, in the myeloproliferative 
diseases, where proliferation is enhanced and differentiation is initially normal, the disease 
most likely progresses to acute leukemia when a second hit impairs differentiation. 
Increased macrophage function with increased cytokine secretion, changes in microvessel 
density, immunologic abnormalities (which are often found in aplastic anemia patients as 
well) and absence of circulating NK T cells wereidentified in patients with MDS (Fujii et al, 
2003).  
2.4.1. Cytogenetic abnormalities 
The search for the mechanistic basis of MDS was fueled largely by the identification of 
recurrent cytogenetic abnormalities that are associated with specific clinical scenarios. The 
common chromosomal abnormalities found in MDS include abnormalities in 17p, loss of Y, 
5q–, 7q– or monosomy 7, trisomy 8, 11q23 abnormalities, del 12p and 20q–, and in half of the 
patients, a normal chromosome pattern. None of these abnormalities is specifically associated 
22 
 
 
with MDS, as all can be seen in AML and some in the myeloproliferative diseases. The cause 
of MDS is usually unknown, although it can occur after exposure to radiation, certain 
environmental toxins, such as benzene, or after treatment of a primary malignancy with 
alkylating agents or topoisomerase II inhibitors (PedersenBjergaard et al, 1995).  
The presence of t (15; 17), t (8; 21), inv (16), and other specific abnormalities in AML but not 
MDS seems to reflect true differences in their biology. Recurrent chromosomal translocations 
in AML produce fusion transcription factor proteins that act as potent transcriptional 
repressors (most likely targeting genes that are required for normal hematopoietic cell 
differentiation), whereas some fusion proteins, such as those that contain the transcriptional 
regulator MLL, appear to function as potent activators of (Hox) gene expression. Deletions, 
numerical abnormalities, and unbalanced translocations are more commonly seen in MDS, and 
translocations specifically associated with MDS are rare.  
The t (3; 21), which is documented in MDS and CML blast crisis, is one of the first recurrent 
MDS-associated cytogenetic abnormalities to be molecularly deciphered. The translocation 
rearranges the AML1 and MDS1–EVI-1 genes, fusing the N terminus of AML1 with a small 
portion of MDS1 and nearly all of EVI-1. Both components of the AML1–MDS1/EVI-1 
fusion protein appear to play critical roles in deregulating hematopoiesis. AML1 (also known 
as CBF  or Runx1, for Runt-related protein 1) binds DNA with its non-DNA binding partner 
CBFβ. Lack of either AML1 or CBFβ is embryonically lethal because of the absence of 
definitive hematopoiesis and a distinct pattern of central nervous system hemorrhage (Wang et 
al, 1996;Okuda et al, 1996).  
The AML1 gene is mutated at low frequency in MDS, but at much higher frequency in AML 
M0, and in treatment-related or radiation-induced MDS (Harada et al, 2003). Whereas the 
mutations found in M0 AML are often bi-allelic, those found in MDS are generally mono-
allelic and result in AML1 insufficiency rather than generating a dominant negative protein. 
Most of the AML1 mutations in AML cluster in the Runt (DNA binding) domain and impair 
the binding of AML1 to DNA but not to CBFβ. The AML1 mutations, found in MDS, occur 
more often in the C-terminus of the protein and truncate the protein, eliminating its 
transactivating domain (Osato, 2004).  
Some MDS patients with an interstitial deletion within the long arm of chromosome 5 (5q–) 
have the "5q– syndrome," whereas others do not. The 5q– syndrome, as defined by the WHO, 
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consists of an isolated 5q– cytogenetic abnormality, associated with macrocytic anemia, a 
normal or elevated platelet count, unilobular megakaryocytes, and a low propensity to develop 
AML (Vardiman et al, 2002a).  
Although the presence of 20q– in MDS has a favorable prognosis, the critical genes deleted 
from this region also remain unknown. A gene that encodes a histone-binding protein within 
the commonly deleted region (CDR) on chromosome 20q12 was identified. The CDR 
contains a polycomb group gene, the L (3) MBTL1 gene (MacGrogan et al, 2001).  
Several laboratories have focused on the commonly deleted region on 7q that is associated 
with MDS. Given the involvement of polycomb and trithorax group genes in AML and MDS 
and the importance of Hox gene expression in hematopoiesis and leukemogenesis, members of 
this family continue to be interrogated, such as the MLL5 gene (a member of the MLL family 
of genes), which is deleted by the 7q– deletion (Side et al, 2004).  
Several publications describe the transcript profiles of purified stem cell fractions obtained 
from the bone marrow of patients with MDS (isolating either CD34+ cells or AC133 
expressing cells). Among the over expressed genes, the Delta-like protein (Dlk1) reported to 
be up-regulated by several groups (Miyazato et al, 2001;Pellagatti et al, 2006). Consistent up-
regulation of interferon- –inducible genes has also been reported: IFITM1 and IFIT1 mRNA 
levels, and TRAIL, another interferon stimulated genes are up regulated in a substantial 
fraction of the MDS patients. 
2.4.2. Immune system and MDS  
T-cell dysregulation is definitely associated with bone marrow failure in AA and large 
granular lymphocyte leukemia (LGLL), which share several clinical features with MDS. 
Immunosuppressive therapy (IST) in MDS was applied in cases with bone marrow 
hypocellularity; a clinical feature that is commonly associated with AA and observed in 
approximately 15% of MDS cases (Young & Maciejewski, 1997). Numerous abnormalities in 
function appear to contribute to impaired hematopoiesis including elevated plasma levels of 
several cytokines such as tumor necrosis factor-alpha (TNF-α) (Molnar et al, 2000) and 
interferon-gamma (IFN-γ) (Selleri et al, 2002), which are well-known contributors to AA 
pathogenesis. Many investigators have now confirmed that cytopenias are corrected by T-cell 
depleting immunotherapy in some MDS patient (Kochenderfer et al, 2002b). A hallmark of T-
cell dominant autoimmunity is the expansion of T-cell clones with restricted diversity that 
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possess a limited T-cell receptor (TCR)-Vβ repertoire. Limitation in TCR-Vβ 
complementary-determining region 3 (CDR3) diversity and clonal expansion of T cells in 
association with bone marrow suppression suggests that escape from peripheral tolerance and 
recognition of self-antigens may contribute to suppressive hematopoiesis (Epling-Burnette et 
al, 2007). The identity of one antigen, that drives abnormal T-cell clonal expansion that 
contributes to impaired hematopoiesis in patients with a trisomy 8 cytogenetic abnormality, 
was confirmed (Sloand & Rezvani, 2008). Clonally expanded CD8+ cells with reduced TCR-
Vβ repertoire diversity and direct cytotoxicity of autologous trisomy 8 hematopoietic 
progenitors was observed in vitro, but no CD8+ T-cell self-reactivity was observed in MDS 
patients with 5q- and monosomy7 chromosomal abnormalities (Sloand et al, 2005). The fact 
that a small number of trisomy 8 cells were present in bone marrow and could be detected 
using fluorescence in situ hybridization (FISH) long before cytogenetic conversion by 
standard metaphase karyotyping, suggests that trisomy 8 aneuploidy may be an early event in 
MDS. It was hypothesized that the CTL response was initially triggered by abnormal stem 
cells but the bone marrow failure was subsequently mediated by a ‘bystander’ CTL response 
against healthy hematopoietic cells. The Wilms’ tumor-1 (WT1) protein, which is localized 
on chromosome 8, and thus over-expressed in MDS patients with trisomy 8, represents a well-
defined target of self-reactive CTLs in immunosuppressive therapy (IST) responsive patients 
(Chen et al, 2004). Since the mechanisms contributing to immune pathophysiology and 
patient selection criteria for IST remain elusive in patients without trisomy 8, a search for 
predictive biomarkers is critically necessary. Expansion of PNH-type cells were reported in 
about 20% of the patients with lower-risk MDS and that phenomenon was linked in some 
studies to IST responsiveness (Wang et al, 2002). It was documented that inversion of the 
CD4/CD8 ratio was strongly associated with response to therapy. The loss of CD4+cells was 
inversely correlated to the proliferative T-cell index before treatment in IST-responsive 
patients suggesting that proliferation and accelerated CD4+ T-cell turnover may be important 
in disease pathogenesis (Zou et al, 2009). A discovery of T-cell receptor (TCR) antigen 
reactivity in patients with aggressive homeostatic proliferation, without trisomy 8, is 
necessary to determine the precise relationship between CD4+ T cells, HLA DR15, and 
homeostatic turnover as an alternative mechanism of autoimmunity in MDS. 
 2.5. Clinical features of MDS 
The evolution of MDS is often slow and the disease may be found by chance when a patient 
has a blood count for some unrelated reason. The symptoms of myelodysplastic syndrome are 
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those of anemia, infections or of easy bruising or bleeding. In some patients, transfusion 
dependent anemia dominates the course, while in others recurring infections or spontaneous 
bruising and bleeding is the major clinical problem. Different people are affected in different 
ways by myelodysplastic syndrome, and its symptoms can range from mild to very severe. 
Some people may only have long-term (chronic) anemia. Shortages of one or more types of 
blood cells cause most symptoms of MDS. Patients may have symptoms such as weight loss, 
fever and loss of appetite. 
2.6. Laboratory findings 
Peripheral blood pancytopenia is a frequent finding. The red cells are usually macrocytic or 
dimorphic but occasionally hypochromic; normoblasts may be present. The reticulocyte count 
is low. The cellularity of bone marrow is usually increased (Table 3). The typical 
morphological abnormalities in MDS include (Figure 13): megaloblasts, dissociated 
maturation of the nucleus and cytoplasm, abnormal multinucleated erythroblasts with three or 
more nuclei, and ringed sideroblasts in the erythrocytic lineage. In addition to hyper-
segmented or hypo-segmented neutrophils (pseudo Pelger-Huët nuclear anomaly), reduced or 
missing granules, and peroxidase-negative neutrophils in the granulocytic lineage; and 
micromegakaryocytes, megakaryocytes with multiple, isolated disc-shaped nuclei and giant 
platelets in the megakaryocytic lineage. 
Table 3: Diagnostic standards for Myelodysplastic syndrome. 
 
1. Peripheral blood cytopenia. 
2. Cellular bone marrow. 
3. Chronic and refractory course. 
4. Exclusion of underlying illnesses or administration of drugs. 
5. Exclusion of other known blood disorders. 
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Figure 13: Morphological abnormalities in MDS. (1) Giant multinucleated erythroblast, (2) 
Megaloblast showing dissociated maturation of nucleus and cytoplasm, (3) Ringed Sideroblast, (4) 
Large hypersegmented neutrophil, (5) Mature neutrophil without nuclear lobes, (6) 
Micromegakaryocyte, (7) Micromegakaryocyte with disc-shaped, separated nuclei, (8) Giant platelets.  
2.7. Treatment of MDS 
The standard care for patients with myelodysplastic syndrome (MDS) and decreased blood 
counts is constantly changing. Supportive therapy, including transfusions of the cells that are 
missing (i.e. RBCs, platelets), and treatment of infections are the main treatments. The US 
Food and Drug Administration recently approved new drugs such as 5-azacytidine, 5-aza-2-
deoxycytidine (Fenaux et al, 2007), and lenalidomide (List et al, 2005) for the treatment of 
myelodysplastic syndrome (MDS). Higher risk MDS patients usually need aggressive 
therapy, but much depends on the age and condition of the patient. Younger patients with 
high-risk disease are considered for front-line chemotherapy approaches followed by 
immediate allogeneic stem cell transplantation. For older patients, who constitute the 
majority, intensive chemotherapy is rarely considered. Instead, the strategy focuses on 
development of active and safe treatments for newly diagnosed patients as well as those who 
have failed the standard of care based therapies (Malcovati et al, 2007). 
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3. Aplastic Anemia 
3.1 Definition  
Aplastic anemia is defined as the failure of bone marrow to produce blood cell components. 
The hallmarks of the disease are pancytopenia and a hypo-cellular bone marrow.  
3.2. Etiology 
Most patients had a diagnosis of idiopathic disease in which no cause is apparent (Doney et 
al, 1997). Inherited forms of the disorder are rare and consist of Fanconi’s anemia, 
dyskeratosis congenital, and Schwachman syndrome.  
3.3. Clinical Presentation  
The signs and symptoms of patients presenting with aplastic anemia are typically related to 
the decrease or absence of peripheral blood cellular components. The clinical presentation 
ranges from insidious to dramatic. Because platelets are depleted early in the process of the 
disease, dependent petechiae, bruising, gum bleeding, buccal hemorrhage, epistaxis, or retinal 
hemorrhage may be among the first presentations. Because of anemia, patients may complain 
of shortness of breath, fatigue, or chest pain. Neutropenia or leucopenia may result in fever, 
chills, or infections. Hepatosplenomegaly, lymphadenopathy, or bone pain are less common in 
patients with aplastic anemia, but these findings should alert the physician to other diagnoses, 
such as infection, leukemia, or lymphoma. 
3.4. Pathophysiology of aplastic anemia   
In most cases, aplastic anemia behaves as an immune-mediated disease. Cellular and 
molecular pathways were mapped in some detail for both effectors (T lymphocyte) and target 
(hematopoietic stem and progenitor) cells. The combination of exposure to specific 
environmental precipitants, diverse host genetic risk factors, and individual differences in the 
characteristics of the immune response likely account for the disease’s infrequency, variations 
in its clinical manifestations, and patterns of responsiveness to treatment (Young, 2006). 
Three decades ago, an immune mechanism was first implicated in the pathogenesis of aplastic 
anemia (Hirano et al, 2003b). Since then, accumulating evidence supports the hypothesis that 
immune mechanisms contribute to the pathogenesis of AA. Immunosuppressive therapies 
incorporating antithymocyte globulin, corticosteroids, cyclosporine, and/or cyclophosphamide 
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were successfully used in the treatment of patients with AA with response rates ranging from 
50% to 80% (Bacigalupo et al, 1995), suggesting that pancytopenia and bone marrow failure 
in at least some AA patients are immunologically mediated. Furthermore, in vitro studies have 
also supplied supportive evidence for an immune-mediated suppression of hematopoiesis in 
AA. These include inhibitory effects of AA patient lymphocytes on hematopoietic 
stem/progenitor cell (HSPC) growth (Kagan et al, 1976), overproduction of myelosuppressive 
cytokines such as interferon-  (IFN-gamma) and tumor necrosis factor-  (TNF-alpha) by 
patient bone marrow cells (Zoumbos et al, 1985), and an increased population of activated 
suppressor T cells. Taken together, these data suggest that at least some cases of AA involve 
autoimmune phenomena that target hematopoietic tissue, probably HSPCs. By establishing T-
cell lines or clones from an involved organ and analyzing their specificity, investigators have 
successfully identified unknown target antigens in organ-specific autoimmune diseases and 
neoplasms (Steinman, 1996). Previous studies with T cells from AA patients have identified a 
pathogenic role for both CD8+ and CD4+ T cells. Peripheral blood T cells capable of 
suppressing in vitro growth of HSPCs belong mainly to the CD8+ fraction (Harada et al, 
1985). The importance of CD4+ cytotoxic T cells in the pathogenesis of AA was also 
described. Several CD4+ T-cell clones that can lyse autologous hematopoietic cells in an HLA 
class II-restricted fashion were isolated from AA patients (Nakao et al, 1997). The work of 
Hirano et al (Hirano et al, 2003a) proved that humoral immune responses to hematopoietic 
antigens could be detect in AA patients. Moreover, in 39 % of aplastic anemia patients 
included in the study antibodies against “kinectin” were documented. 
4. PNH, MDS and aplastic anemia 
PNH is closely related to aplastic anemia and certain forms of MDS. Many aplastic anemia 
patients have different degrees of PNH involvement. PNH may develop from aplastic anemia, 
or aplastic anemia and low counts might be a complication of PNH. Many specialists believe 
that aplastic anemia sets the conditions, which are advantageous for the growth of PNH stem 
cells and for the development of PNH (Nissen & Schubert, 2002). The clarification, as to why 
PNH and aplastic anemia occur so frequently together, might help us to understand the 
pathogenesis of these diseases and develop new specific treatments. For MDS/AA syndrome, 
the core or common denominator is a PIG-A mutated population that has undergone further 
mutation (PIG-A plus X). Rather than being separate diseases, they may be a part of a 
syndrome (Fig 14). 
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Patients with primary normo/hypercellular MDS or PNH are not part of the syndrome; 
however, all patients who develop hypoplasia/aplasia invariably belong to it, since their 
natural history includes PNH and/or MDS, whether AA was originally virus-, drug-, toxin-
induced or idiopathic. A sequence of events leads to development of aplastic anemia/MDS 
and PNH was depicted in (Fig 15). In the first step a noxious agent (i.e. a virus, a toxic agent 
or a drug) causes transient HSC damage and induces repair involving hyperproliferation 
during which the incidence of PIG-A mutations is increased, since PNH clones are genetically 
unstable and disposed to further mutations. In the second step an additional genetic changes 
providing a growth advantage are likely to occur. This would lead to the presentation of an 
aberrant internal image on MHC molecules and thus to T-cell recognition and activation (Fig 
15 A). Third step, the immune reaction against transformed HSC can be of three different 
types (Fig 15B, Nissen & Schubert, 2002). 
 
 
 
Figure 14: Proposed pathogenic link between aplastic anemia (AA), myelodysplasia (MDS) 
and paroxysmal nocturnal hemoglobinuria (PNH). 
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Normal cell (HSC), Cells with an isolated PIG-A mutation,  PIG-A mutated cells with abnormalities 
conferring a growth advantage, Cells with additional cytogenetic abnormalities, T lymphocytes, 
Transformation route of HSC,  Cytotoxic activity, 
 Putative T cell activation,  Missing T cell activation.  
Figure15: A hypothetical sequence of events leads to PNH or aplastic anemia, (A) HSCs with an 
isolated PIG-A-mutation occur in normal bone marrow. Exposure to toxic agents causes cellular 
damage and induces proliferative stress in HSC. PIG-A mutated cells or normal cells undergo 
mutations within genes involved in proliferation and differentiation leading to predysplasia. (B) 
Predysplastic cells alert the immune system, which reacts either with anergy, leading to expansion of 
abnormal clones, with a hyperreactive autoimmune reaction leading to severe aplastic anemia or with a 
selective immune reaction leading to cure. Modified according (Nissen & Schubert, 2002). 
Hyporeactive/anergic response: In patients with a compromised immune system, the 
abnormal population expands and displaces normal HSC. PNH patients, though surviving 
long term with the abnormal clone have signs of immune incompetence: they are prone to 
infections and have low endogenous IL-2 production. Clinically, these patients present with 
PNH if the clone is stable and does not progress to leukemia or with MDS/AML if the clone 
undergoes further transformation. 
Hyperactive response: In patients predisposed to autoimmunity, the immune reaction against 
the abnormal population extends to normal HSCs by the mechanism of ‘epitope spreading’. 
This causes severe aplasia with neither normal nor abnormal cells detectable in the BM. The 
more vigorous the immune reaction, the more acute and serious is BM failure and thereby the 
chance of transformed clones to be decimated. This immune attack puts pressure on mutated 
cells that attempt to survive by the development of new, potentially resistant clones. 
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Selective response: A specific immune reaction destroys the abnormal population, sparing 
normal HSC, leading to reconstitution of normal hematopoiesis. Clinically unrecognized 
expansion and subsequent immunological destruction of small potentially life-threatening cell 
populations is probably the most frequent event. 
Murakami et al presented in 2002 (Murakami et al, 2002c) the first experimental evidence 
that supports the immunologic selection hypothesis for the clonal expansion of PNH cells and 
demonstrated that GPI  hematopoietic cells become dominant in a mouse model on selection 
by allogeneic CD4+ T cells. The study showed that GPI+ APCs present the antigen derived 
from GPI-anchored proteins on MHC class II molecules, whereas GPI  APCs do not. GPI-
anchored proteins like other cell surface trans-membrane proteins would reach, via the 
endocytic pathway, a compartment where proteins are processed for presentation on MHC 
class II molecules. Proteins that are normally GPI anchored are not expressed on the surface 
of GPI  APCs; hence, there is no presentation on the MHC class II molecules. They 
suggested that if the relevant autoantigen is derived from GPI-anchored proteins, PNH cells 
might be resistant to CD4+ CTL (Figure 16A). They demonstrated also using in vitro systems 
that GPI  APCs do not effectively stimulate antigen-specific and allogeneic CD4+ T cells 
efficiently, which suggests that some GPI-anchored protein on APCs acts as a ligand for 
costimulatory molecules on T cells (Figure 16B, Murakami et al, 2002b). 
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Figure 16: Two experimentally tested models. (A) A putative autoantigen recognized by CD4+ T cells 
is derived from GPI-anchored proteins. GPI+ cells (left) process GPI-anchored proteins and present 
antigenic peptides on MHC class II molecules; whereas GPI  cells (right) do not present such antigenic 
peptides. (B) Some GPI-anchored protein is a ligand for some costimulatory molecules on CD4+ T cells. 
GPI+ cells (left) efficiently stimulate CD4+ T cells; whereas GPI  cells (right) do not. Modified 
according to (Murakami et al, 2002a).    
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5. Aim of the Study 
The mechanism of clonal expansion of GPI-AP-deficient cells in PNH is still obscure. The 
fact that PIG-A mutation itself does not confer a proliferative advantage to HSCs suggests a 
second event to be responsible for clonal expansion of mutant cells. Two different hypotheses 
have been proposed to explain the clonal expansion in PNH, one assuming an immune escape 
mechanism and the other proposing an intrinsic second mutational event within clonal cells. 
In both hypotheses, the immune system supposed to play an important role. In the first theory 
(immune selection hypothesis), a defect in the immune system leads to immune attack 
directed against special antigens. GPI deficient cells can escape the immune system attack 
either by no expression of such antigens or by less susceptibility against cytotoxic attack of 
autoimmune T lymphocytes. In the second theory (clonal expansion through genetic 
alterations), the immune system recognizes the genetic alterations in target cells and produces 
antibodies against the modified antigens. Hence, the identification of these antigens will prove 
the occurrence of such alterations in the target cells. The identification of target antigens of 
the antibodies in PNH sera will give information about the pathophysiology of the disease and 
may give support to one or both theories. In MDS patients, the expansion of PNH-type cells 
was also reported and that phenomenon was linked in some studies to immunosuppressive 
therapy responsiveness. Identification of auto-antigens in MDS will demonstrate the immune 
mechanism of cytopenia in the disease. The aim of the study was to identify the target 
antigens of the immune system in PNH patients and MDS, study the serological reactivity of 
PNH patients, and compare it with that of healthy individuals, aplastic anemia, and MDS 
patients. Moreover, the genes that encode the target antigens in PNH were analyzed and the 
possibility of alterations of these genes by the patients was investigated.  
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V. Material and methods 
1. Immunoscreening of cDNA expression library  
Screening for candidate antigens was performed using the serological identification of 
antigens by recombinant expression cloning (SEREX) approach. This approach was first 
established by Pfreundschuh’s group and applied for detection of tumor antigens in 1995 (Fig 
17, Sahin et al, 1995). A human fetal liver cDNA expression library (Takara Bio Europe, 
Saint-Germain-en-Laye, France) was used as Antigens source. XL1-Blue Escherichia coli 
(Takara Bio Europe, Saint-Germain-en-Laye, France) was transfected with recombinant 
phages, plated on agar plates, and cultured at 37° C. Expression of recombinant proteins was 
induced by incubating the bacterial  lawns with isopropyl β-D-thiogalactoside (IPTG) and the 
released proteins were Transferred to nitrocellulose filters (Hybond C-Extra; Amersham 
Pharmacia Biotech, Piscataway, NJ) by incubating at 37 °C for 90 minutes. Filters were then 
washed in TBST (10 mM Tris [tris (hydroxymethyl) amino methane], 150 mM NaCl, 0.05% 
Tween 20, pH 8.0) and blocked one hour with blocking buffer (5% wt/vol non-fat dry milk 
[Nestle, Solon, OH] in TBST). Filters were then incubated with patient sera diluted at 1:100. 
Specific binding of antibodies to recombinant proteins was detected by incubation with 
alkaline phosphatase-conjugated goat antihuman IgG antibody (Promega, Madison, WI) 
diluted at 1:2500. Visualization of the antigen-antibody complex was accomplished by 
staining with 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium (Promega). 
Complementary DNA inserts from positive clones were subcloned, purified, and in vivo 
excised to plasmid forms (Takara Bio Europe, Saint-Germain-en-Laye, France) according to 
the manufacturer’s instructions. The DNA inserts were subsequently sequenced with 
appropriate sequencing primers.  
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Figure 17: SEREX Method as described by Sahin et al (Sahin et al, 1997). 
 
1.1. Preparation of patient’s sera  
Sera from 10 MDS patients were obtained at the Department of Hematology, Oncology and 
Clinical Immunology, Düsseldorf University Hospital (Düsseldorf, Germany). The sera were 
stored at - 80° C until use. The characteristics of all MDS patients are shown in table 4. 
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Table 4: Characteristics of MDS patients included in the study. 
Patient 
number 
Age 
and 
Gender 
Hemoglobin 
level g/dl 
Blood 
transfusion 
Bone marrow Diagnosis 
IPSS 
classification 
WHO 
classification 
1 19 M 6.5 4/ month Dysplasia in all 3 
cell lineage, 4 % 
Blasts, hypocellular 
BM 
Low-risk RCMD 
2 67 F 8.3 Unknown Dysplasia in all 3 
cell lineage, 4 % 
Blasts, hypocellular 
BM 
Low-risk RCMD 
3 60 F 9.3 2/ month Dysplasia in all 3 
cell lineage, 9 % 
Blasts, hypocellular 
BM 
High-risk REB I 
4 64 F 7.1 2/month Dysplasia in all 3 
cell lineage, 1 % 
Blasts, hypocellular 
BM 
Low-risk RCMD 
5 65 M 8.7 Unknown 3 % Blasts, 
normocellular BM  
Low-risk MDS with del 
(5q) 
6 63 F 9 Unknown 2 % Blasts Not defined MDS with del 
(5q) 
7 40 M 7.4 No 6 % Blasts, 
normocellular BM 
High-risk RAEB I 
8 64 M 6.4 Yes 
Unknown 
1 % Blasts Low-risk MDS with del 
(5q) 
9 61 M 7.3 Yes 
Unknown 
1 % Blasts, 
normocellular BM 
Low-risk MDS with del 
(5q) 
10 55 M 7.8 Yes 
unknown 
15 % Blasts, 
hypocellular BM 
High-risk RAEB II 
 
Sera from 10 patients with PNH were obtained during routine diagnosis or follow-up at the 
Department of Internal Medicine Ι, Saarland University Medical School (Homburg, Germany) 
and the Department of Hematology and Haemostaseology, University of Vienna (Vienna, 
Austria). Table 5 describes the characteristics of the PNH patients included in our study. 
Diagnosis of PNH had been established by flow cytometry. 
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Table 5: Characteristics of PNH patients included in the study. 
 
Sera from five patients with newly diagnosed aplastic anemia (without PNH clones) were 
frozen before starting immunosuppressive therapy at the Institute for Transfusion Medicine 
and Clinics for Aplastic Anemia in Ulm (Ulm, Germany). Twenty healthy individuals 
donating blood at the Department of Transfusion Medicine, University of Saarland (Homburg 
Germany) were used as a control group. Patients gave informed consent for blood analysis. 
All sera were stored at - 80° C until use for screening as described below. 
The same amount was taken from each of the 10 PNH sera and mixed together. These mixed sera 
were diluted 1:100 in 1×TBS containing 0.5% (wt/vol) low-fat milk. For preservation, 0.01% 
NaN
3 
was added. These diluted sera were stored at +4°C and used for SEREX screening. In the 
same way, an AA pool, MDS pool and normal individual pool were made.  
1.2. Preparation of host bacteria and transfection 
The glycerol stock of XL1-Blue’MRF E.coli bacterium was streaked onto a Luria-Bertani 
(LB) tetracycline agar plate (tetracycline, 12.5 µg/ml) and the plate was incubated at 37°C 
overnight. Next day, a single colony of bacteria was picked from the LB agar plate and put 
into a 300 ml conical flask that contains 50 ml of LB medium supplemented with 0.2 % (w/v) 
maltose, 10 mM MgSO4 and tetracycline (12.5 µg/ml). The bacteria were grown at 37°C for 
4-6 hours under shaking, until the density of bacteria reached at an OD600 of 0.5. The cells 
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were spun down at 500×g for 10 minutes and the supernatant was discarded. The cells were 
suspended gently in 25 ml sterile water with 10 mM MgSO4, diluted to an OD600 of 0.5 with 
sterile water containing 10 mM MgSO4. The bacteria were stored at 4°C and ready for 
transfection. 
1.3. Transfection with plasmid 
600 µl XL1-Blue MRF’ E.coli were incubated with appropriately diluted human fetal liver 
cDNA expression library (Takara Bio Europe, Saint-Germain-en-Laye, France) (4×103 
recombinant phage/per 15 cm plate) at 37°C for 15 minutes to allow phage attach to the cells. 
Expression of fusion proteins in lytic phages was induced by adding 20 µl of 2 M isopropyl-1-
thio-β-D-galactopyranoside (IPTG) and 5 ml of top agar (pre-warmed at 52°C) to the bacteria 
and phage mixture. The top agar was quickly poured onto LB agar plate under carefully 
swirling in order to distribute the cells evenly. The plates were inverted and incubated at 37°C 
until plaques were visible (normally overnight).  
1.4. Transfer of recombinant proteins onto nitrocellulose 
When the plaques were grown to 1 mm of diameter on the plates, nitrocellulose membrane 
was placed onto each agar plate to absorb the protein from the plaques. A needle was used to 
prick through the membrane and agar with three asymmetric points for orientation. The plates 
were placed at 37°C for 1 hour, and then cooled at 4°C for 30 minutes before removing the 
nitrocellulose membranes from them. The membranes were washed in TBST (TBS containing 
0.5% tween 20) for 10 minutes, under shaking. A piece of soft sponge was used to remove the 
residual agar from nitrocellulose membranes and the membranes were washed with TBST 
two times additionally, then blocked with 5% (W/V) low-fat milk in TBS at room temperature 
for at least 1 hour, and washed with TBS twice for 20 minutes.  
1.5. IgG pretest 
To exclude signals derived from the binding of secondary antibodies to expressed IgG-cDNA 
fragments that are included in the library, membranes were incubated with alkaline 
phosphatase-conjugated goat anti-human IgG Fcγ (Dianova, Hamburg, Germany) diluted 
1:2.500 for 1 hour at room temperature. Subsequently, after washing in TBS twice under 
shaking, reactive phage plaques were visualized by incubating with 5-bromo-4-chloro-3-
39 
 
 
indoly-phosphate (BCIP) and nitroblue tetrazolium (NBT) at 37 °C in dark condition for 10 to 
30 minutes. A pencil used to mark signals. 
1.6. Immunostaining 
The membranes were incubated with 20 ml diluted sera (1:100) at 4 ºC overnight, under 
gently shaking. Next day, the sera were collected and the membranes were washed twice in 
TBS for 30 minutes. This was followed by an incubation with an alkaline phosphatase-
conjugated goat anti-human IgG Fcγ (Dianova, Hamburg, Germany) diluted 1:250 for 1 hour 
at room temperature. After washing in TBS twice under shaking, reactive phage plaques were 
visualized by staining with 5-bromo-4-Chloro-3-Indolyl-Phosphate (BCIP) and nitroblue 
tetrazolium (NBT) at 37°C in dark condition for 5 to 10 minutes. 
1.7. Isolation of positive clones  
The stained membranes were checked carefully and the positions of reactive phage plaques 
were marked with a pencil. According to the marks, the reactive phage plaques were isolated 
from the original agar plates with sterile glass pipettes and transferred to a micro centrifuge 
tube containing 500 µl of SM buffer (NaCl, MgSO4,Tris pH 7.5, Gelatin ) and 20 µl of 
chloroform. The tube was vortexed briefly and shaken for 1-3 hours at room temperature to 
release the phage particles into the SM buffer then storage at 4°C.  
2. Sequence analysis of identified clones 
The isolated phages from the original plate were diluted at different concentrations in SM 
buffer and the appropriate concentration was chosen to transfect bacteria. The procedures 
were performed as described above (see 1.3). The reactive clone was subcloned to 
monoclonality and submitted to in vivo excision of pTripelex vector and further serological 
assessment.  
2.1. Conversion of the vector  
The conversion of λTriplEx2 clone to a pTriplEx2 plasmid involves in vivo excision and 
circularization of a complete plasmid from recombinant phage. The plasmid is released 
because of Cre recombinase- mediate side-specific recombination at the loxP sites flanking 
the embedded plasmid (Figure 18). 
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Figure 18: Conversion of a recombinant λTriplEx2 to the corresponding pTriplEx2. The 
λTriplEx2 MCS is located within an embedded plasmid, which is flanked by loxP sites at the λ 
junctions. Transduction of a λTriplEx2 lysate into E. coli strain BM25.8 promotes Cre recombinase-
mediated release and circularization of pTriplEx2 at the loxP sites. pTriplEx2 carries the bla gene for 
ampicillin resistance and the pUC ori for autonomous replication in E. coli. The MCS provides several 
unique restriction sites flanking the SfiI A & B sites to facilitate the subcloning and analysis of inserts. 
In this system, E.coli BM 25.8 provides the necessary Cre recombinase activity. The released 
version plasmid differs from the pTriplEx2 by a 100-bp loxP insert at the Cla site. The 
excised plasmid is propagated stably in E.coli. The process was done in the following steps: 
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Single, isolated colonies from the working stock plate of BM25.8 host cells were picked and 
used to inoculate 10 ml of LB broth in a 50-ml test tube or Erlenmeyer flask. The culture was 
incubated at 31°C overnight with shaking (at 150 rpm) until the OD600 of the culture reached 
(1.1–1.4). After that, 100 µl of 1 M MgCl2 were added to the 10-ml overnight culture of 
BM25.8 (10 mM final concentration of MgCl2). A well-isolated positive plaque from 
secondary- or tertiary screening plates was picked and placed in 350 µl of 1M lambda dilution 
buffer. After vortexing the plaque, it was incubated at 37°C for 3–4 hours without shaking 
(200–250 rpm). Then, in a 20-ml test tube: 200 µl of overnight cell culture was combined 
with 150 µl of the eluted positive plaque. The Mixture was incubated at 31°C for 30 min 
without shaking then 400 µl of LB broth was added and incubated at 31°C for an additional 1 
hr with shaking (225 rpm). 
Using a sterile glass spreader, 1–10 µl of infected cell suspension was spread on an 
LB/carbenicillin (or Ampicillin) plate to obtain isolated colonies and incubated at 31°C 
overnight. Several well-isolated colonies from each clone were picked and prepared plasmid 
 
Figure 19: Restriction Map of λTriplEx2. 
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DNA separately from each one. The isolated plasmid DNA should be pure enough for direct 
sequencing. Provided pTriplEx2 sequencing primers used with standard Ds-DNA-sequencing 
protocol. 
2.2. Restriction enzyme digestion of plasmid DNA  
Because the high quality of sequence data depends directly on the quality and quantity of the 
template DNA, it is important to make a restriction digest of the plasmid DNA and evaluate 
the size and the quantity of the cloned DNA insert. The mixture of enzyme reaction contains 1 
µl of plasmid DNA, 0.5 µl of EcoRI and Xho I enzyme (Fermentas, 10U/µl), 4 µl of 
10×buffer (Y+/TanqoTM, Fermentas), and H2O to the final reaction volume of 20 µl. The 
reaction was incubated at 37°C for 3 hours. To check the progression of a restriction enzyme 
digestion, 1% agarose gel with ethidium bromide in 1×TAE buffer was prepared. Digested 
plasmid DNA and DNA markers were loaded onto the gel. Electrophoresis was performed at 
80 V for 1 hour. After electrophoresis, the gel was placed on an UV light box and a picture of 
DNA separation pattern was taken with a Polaroid camera.  
2.3. Determination of nucleotide sequence  
2.3.1. Sequencing reaction  
Double strand plasmid DNA with insert was sequenced in both directions by the 
dideoxynucleotide termination method (Sanger et al, 1977). The four reactions mixes were set 
up for each template, respectively, each containing all four deoxynucleotides triphosphates 
(dNTPs) and one of the four dideoxynucleotide triphosphates (ddNTPs), to generate four 
different sets of fragments. The synthesis of DNA strand is initiated at a vector specific site to 
which the primer is annealed and terminated by the incorporation of a ddNTPs.  
The sequence reaction was performed using the SequiTherm EXCELTM DNA Sequencing 
Kits-LC (Epicentra Technologies, Madison, WI) with fluorescent-labeled primers. The 
procedure was done as follows: for each template, 2 µl of each termination mix G, A, T, C 
was dispensed into four different microcentifuge tubes labeling with G, A, T and C. The 
master mixture was prepared by mixing 7.2 µl of sequence buffer, 0.5 µl of each labeled 
primer (2 pmole, IR41-labeled reverse and universe primer), 50-250 fmoles of DNA template, 
1 µl of DNA polymerase (5 u/µl) and sterile, deionized H2O to bring total volume to 17 µl. 
Followed by dispensing 4 µl of the mixture to each of four tubes containing Termination Mix 
(G, A, T, C), respectively. A drop of mineral oil was placed on top of each reaction mixture, 
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and tubes were put into a TRIO-Thermoblock (Biometra, Göttingen, Germany). Sequencing 
reaction was started at 94°C for 5 minutes to denature double-stranded templates. Then 30 
cycles were performed, during each cycle, the reaction was raised to 94°C for 1 minute to 
denature double-stranded templates, lowered to 60°C for 1 minute to anneal the primer to the 
template, and then raised to 70°C for 1 minute for the elongation step. When the PCR was 
finished, 4 µl of stop / loading buffer was added to each reaction tube.  
2.3.2. Denaturing polyacrylamide gel electrophoresis 
The denaturing polyacrylamide gel was prepared in 0.2 mm thickness using a set of 41 cm 
long glass plates. The gel contained 30 ml of Sequagel XR (6% National Diagnostics, 
BIOZYM), 7.5 ml of Sequagel buffer, 400 µl of DMSO (Sigma) and 300 µl of 10% fresh 
APS. After the gel had been cast, it was allowed to polymerize for 1 hour at room 
temperature. Then, the gel was installed in a LICOR automatic sequencer (Model 4000L) 
following pre-electrophoresis with 1×TBE buffer at a running condition of 1500 V, 37 mA 
and 50°C for 45 minutes. The loading area of the gel was rinsed carefully by pipetting gently 
up and down and a shark toothcomb was inserted until the teeth just touched the gel, with the 
teeth forming the sidewalls of the wells. In order to separate the synthesized DNA fragment 
from the template strand, and to allow the DNA to flow through the gel before loading 
samples onto the gel, the products of sequencing reaction have to be denatured by heating at 
80°C for 5 minutes and chilled on ice immediately. 1 µl product of each reaction was loaded 
into the wells of the gel according to G, A, T, C in adjacent order. The sequencing reaction 
products are size-separated by the denaturing polyacrylamide gel electrophoresis. Sequence 
alignments were collected and analyzed with DNASIS (Pharmacia Biotech, Freiburg, 
Germany) and BLAST software on NCBI GenBank (Altschul et al, 1990).   
3. Serological analysis of positive clones  
3.1. Preparation of sera  
To remove antibodies in the serum that could react with bacterial or phage components the 
serum used for serological analysis must be pre-absorbed by the following two methods. This 
was only done for sera that were used at high concentration (dilution 1:100).  
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3.1.1. Affinity chromatography absorption  
Antibodies to E. coli and phage components can be removed from serum using affinity 
chromatography that exploits the specific binding of antibody to these antigens held on a solid 
matrix. These antigens are bound covalently to small, chemically reactive beads loaded into a 
column. When serum passes over the column containing the antigen binding beads, antibodies 
to E. coli phage components will bind to the beads on the column, which results in the 
removal of antibodies against bacteria and phages from the serum. In this study, two different 
affinity columns were used for the treatment of the sera.  
a) Preparation of L column  
The L column contains bacteria and phage components. For the preparation of the L column, 
50 ml of LB-Tetracycline-medium containing XL-1 blue MRF’ E. coli is cultured at 37°C 
with shaking overnight. Aliquots of the bacterial culture medium were placed in a 50 ml tube 
and centrifuged at 3000 rpm for 30 minutes to save the pellet. The bacterial pellet was then 
resuspended with 2 ml of 0.01 M MgSO4, of which, 200 µl of insert-free λTriplEx2 phages in 
5 ml of LB-medium. The mixture of phages and bacterial was placed at 37°C for 4 hours 
under shaking for lytic infection. The rest of the bacterial suspension mixed with 5 ml of LB-
medium was added to this cultured mixture to continue incubation for another 2 hours at the 
same conditions as before. Then, the mixture was centrifuged at 8000 rpm for 10 minutes. 
The pellet was saved and resuspended in 10 ml of 1 × MOPS buffer (3-(N-Morpholino)-
propanesulfonic acid) followed by sonication for 10 seconds twice on ice. The disrupted 
bacteria were mixed with 1 ml of affinity adsorbent (Roche Diagnostics GmbH, Mannheim, 
Germany) in a 50 ml Falcon tube. The tube was agitated by overhead rotation at 4°C 
overnight in order to let the affinity adsorbent bind the antigens completely.  
After overnight rotating, the tube containing the antigen binding absorbent should be rinsed in 
20 ml of PBS containing 0.01% NaN3 by rotating at 4°C for 30 minutes. After discarding the 
PBS, 20 ml of 1 M glycine is loaded into the tube to continue rotating for 2 hours at 4°C. 
Finally, the PBS wash is repeated once more. The tube is ready for pre-absorption of serum. 
b) Preparation of M column  
The M column contains only bacteria antigens. The pellet of XL-1 blue MRF’ was directly 
resuspended in 10 ml of 1×MOPS buffer by vortexing. The bacteria were disrupted by 
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sonication and mixed with affinity adsorbent. The procedure is the same as that described 
above for the preparation of the L column.  
3.1.2. Lytic bacteria membrane absorption 
Empty pTriplEx2 phages (pfu 50,000) (without cDNA inserts) were incubated with XL-1 blue 
MRF’ (OD600=0.5) at 37°C for 15 minutes, followed by mixing with top agar without adding 
IPTG and plating on a LB-Tet agar plate. After incubating overnight at 37°C, the phages were 
blotted onto a nitrocellulose membrane and kept at 37°C for 1 hour. The membrane was then 
blocked with 5% low-fat milk and subsequently washed. The main procedure was the same as 
described above. The membrane containing the lytic bacteria was air-dried, stored at room 
temperature and was ready to use for the pre-absorption of the sera.  
3.1.3. Pre-absorption of sera  
The sera were first diluted at 1:50 with 20 ml of 0.5% low-fat TBS and loaded to the M 
columns with rotating overnight at 4°C. Each serum was transferred from the M to the L 
column to continue absorption under the same conditions. After passing through both 
columns, the serum was placed in a plate with a lytic bacterial membrane by shaking at room 
temperature. A new lytic bacterial membrane replaced the lytic bacterial membrane every 4 
hours for four times. Finally, the serum was diluted to 1:100 containing 0.01% NaN3 and 
Thimerosal. The serum was stored at 4° C until use. After passing of the serum, the column 
was regenerated by rinsing in acid condition in order to elute the binding antibodies. 30 ml of 
0.1 M Tris (pH 3) was used to wash the column thrice for 30 minutes at 4°C with rotating, 
followed by a wash in TBS twice 30 minutes. The column can be preserved in PBS containing 
0.01% NaN3 in 4°C for reuse.  
3.2. Phage assay for the detection of serum antibodies  
For the detection of antibodies with binding activity for the proteins in the lytic plaques, sera 
from different individuals and monoclonalized phages from the positive clone were mixed, at 
a ratio of 1:10, with non-reactive phages of the cDNA library as an internal negative control. 
To avoid false negative results due to the decomposition of sera, a clone, PINCH (EMBL 
Data library, Accession No.U09284) known to react with most of human sera, was chosen as 
a positive control for serum quality. The clone for positive control and the clone positive in 
the library screening were used to transfect bacteria, respectively. Then, transfected bacteria 
were mixed with top agar and IPTG by plating on separate quarters of the same agar plate. 
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The plate was incubated in 37°C overnight, followed by blotting onto a membrane and 
serially washed. The 1:100 diluted E coli-absorbed sera were tested with immunoscreening 
procedure as described above. To compare different serum relativities, testing was done in 
parallel and developing was stopped after 5 minutes.  
4. Expression assay by reverse transcription PCR 
4.1. Hematopoietic progenitor cell assay  
CD34+ cells were purified from bone marrow of PNH-1 (which was positive against the first 
isolated clone) and a non PNH patient (as control) using magnetic cells sorting (MCS Kit- 
Miltenyi Biotec , Germany) according to the manufacturer’s instructions. 
4.1.1. Preparation of bone marrow cells 
Bone marrow was collected in 50 mL tubes containing 5 mL PBS + 2 mM EDTA. For 
preparation of single cell suspension of bone marrow cells, it was diluted with 10 x the 
volume of RPMI 1640 containing 0.02 % collagenase B and 100 U/mL DNase and was 
shaken gently at room temperature for 45 minutes. The cells were passed through 30-µm 
nylon mesh (Miltenyi Biotec, Germany); the mesh was wetted with buffer before use. 35 mL 
of diluted cell suspension was layered carefully over 15 mL of Ficol-plaque. It was 
centrifuged for 35 minutes (400 g, +20˚C) in swinging-bucket rotor without brake. The upper 
layer was aspirated leaving the mononuclear cell layer undisturbed at the interphase. The 
interphase cells (lymphocytes, monocytes and the thrombocytes) were carefully transferred to 
a new 50 mL tube. The tube was filled with PBS containing 2 mM EDTA and centrifuge for 
10 minutes (300g, 20˚C). The supernatant was removed completely, and the cell pellet was 
resuspended in a final volume of 300 µl of Buffer for up to 108 total cells.  
4.1.2. Magnetic labeling 
The number of cells was determined using a Neubauer counting chamber, the cell suspension 
was centrifuged at 300g for 10 minutes, and the supernatant was aspirated completely. The 
cell pellet was suspended in 300 µl of buffer up to 108 total cells and 100 µl of FCR blocking 
reagent was added for up to 108 total cells then 100 µl of CD34 Microbeads for up 108 total 
cells. Mixed well and refrigerated for 30 minutes (4-8˚C). 
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After that, the cells were washed using 5-10 mL of buffer for up to 108 cells, centrifuged at 
300 g for 10 minutes. The supernatant were completely aspirated and the pellet was 
resuspended up to 108 total cells in 500 µl of buffer. 
4.1.3. Magnetic separation with LS columns 
A column was placed in the magnetic field of a suitable MACS Separator. The column was 
prepared by rinsing with appropriate amount of buffer (LS: 3 mL). The cell suspension was 
applied onto the column. Unlabeled cells that pass through were collected and the column was 
washed with appropriate amount of buffer. The washing steps were performed by adding 
buffer three times. A new buffer was added only when the column reservoir is empty (LS: 
3X3 mL). The total effluent was collected; this is the unlabeled cell fraction.  
The column was removed from the separator and placed on a suitable collection tube. An 
appropriate amount of buffer (LS: 5 mL) was added onto the column and the magnetically 
labeled cells were immediately flushed out by firmly pushing the plunger into the column. 
The number of cells was determined again and proceeded to RNA extraction. 
4.2. Extraction of Total RNA  
Ribonucleases are very stable enzymes responsible for RNA hydrolysis. RNase A can easily 
survive autoclaving and other standard methods of protein inactivation. To prevent 
contamination of RNase, all glassware used for RNA extraction should be baked for a 
minimum of 3 hours at 250°C. For plastic ware, RNase-free products should be used or be 
treated with DEPC-H2O (de-ionized water treated with diethyl pyrocarbonate) overnight and 
autoclaved for at least 30 minutes. H2O should be treated with 0.1% DEPC 
(Diethylpyrocarbonate, Sigma) overnight under shaking and autoclaved to remove residual 
DEPC.  
Total RNA was isolated by a modification of the single-step acid guanidium thiocyanate 
(GITC)-phenol-chloroform RNA extraction method (Chomczynski & Sacchi, 1987) or by 
using the RNeasy Mini Kit (Qiagen, Germany). Integrity of the RNA was checked by 
electrophoresis, the yield was measured by UV absorption. 5 ml of GITC-buffer was mixed 
with 1% β-mercaptoethanol (Sigma) in a 12 ml tube (Falcon, “white caps”) and the mixture 
was added to about 500 µl cell suspension, and immediately homogenized until a completely 
homogeneous lysate was obtained. Then 0.5 ml of 2 M sodium acetate (pH 4.0), 1 ml of 
chloroform and 4.5 ml of TE-saturated phenol pH 4.5 (Carl Roth GmbH, Karlsruhe, 
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Germany) were added. The mixture was vigorously vortexed and placed on ice for 30 
minutes. To get the phase separation, the mixture was centrifuged (7500g, 4°C) for 15 
minutes and 4 ml upper aqueous layer was carefully transferred to a new tube containing 6 ml 
of isopropanol. After vortexing briefly, the sample was placed at -20°C overnight. A 
subsequent wash with cold ethanol (80%) followed by brief centrifugation. The RNA pellet 
was air dried at room temperature for 15-30 minutes, and dissolved in DEPC-treated H2O. 
Aliquots of RNA were stored at - 80 °C until use.  
For checking the integrity and assessing the amount of RNA, 1µl of RNA mixed with loading 
buffer was placed at 70 °C for 5 minutes and quickly chilled on ice. The sample of RNA and a 
standard of RNA (E. coli RNA) used to evaluate the amount of RNA were loaded in 1% 
formalin/MOPS gel. Electrophoresis was performed with 1×MOPS buffer at 80V for 40 
minutes. RNA pattern was visualized under the UV light.  
4.3. First-strand cDNA synthesis  
For each reaction, 2-5 µg of total RNA was mixed with 1 µl of dT18-oligonucleotide (50 
pmol/µl), 1 µl of dNTP (10 mMol of each dATP, dTTP, dCTP, dGTP) and DEPC-treated H2O 
to a volume of 13 µl. The mixture was heated to 70°C for 5-10 minutes and quickly chilled on 
ice.  
The content of the tube was collected by brief centrifugation and 6 µl of the master mixture 
was added containing 2 µl of 0.1 M DTT, 4 µl of 5 × first-strand cDNA buffer and 0.8 µl of 
moloney murine leukemia virus (MMLV) reverse transcriptase II (GIBCO/Life 
Technologies), followed by pipetting gently up and down for mixing. The reaction was 
incubated for 60 minutes at 42°C, and then the reaction was stopped by heating at 70°C for 15 
minutes. The entire process was performed in a programmable thermocycler (Biometra, 
Germany). The first-strand cDNA was stored at -20°C until use.  
Integrity of the cDNA was proven by amplification of ubiquitously expressed p53 gene 
transcripts in a 30-cycle PCR (Gure et al, 2000), using the following primers: 5’-ACT GAA 
CAA GTT GGC CTG CAC-3’ (sense, exon 10) and 5’-TGC AGA TGT GCT TGC AGA 
ATG-3’ (anti-sense, exon 11). Only those cDNA, that expressed p53 well, were used further.  
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4.4. RT-PCR analysis of identified clones  
To evaluate the mRNA expression pattern of identified clones, RT-PCR was performed by 
amplification of the cDNA from normal and PNH CD34+ cells. The gene-specific primers 
utilized in RT-PCR reactions were designed to amplify the coding sequences of 
corresponding serologically defined antigens and synthesized commercially (MWG, Biotech). 
For MPHOSPH 1, the forward primer (5`- GTGAGTAAAAATGCTCTCAG -3`) and the 
reverse primer (5`- GAAGCTGACTTTAAGAC -3`) were applied. For desmoplakin, the 
forward primer 5`- GGCTTCGAGGGTGTGAAGGGAAAGAA -3`) and the reverse 
primer (5`- TGCGGTGTCCCTTAAGAAGGATGA -3`) were used. 
0.8 µl of first-strand cDNA was amplified using 0.2 U AmpliTaq Gold (Perkin Elmer, 
Weitersadt, Germany), 1 µl of dNTP (10 mMol of each dATP, dTTP, dCTP, dGTP), 1 µl of 
each primer and 3 µl of PCR buffer in a reaction volume of 30 µl. The amplification was 
performed with 35 cycles at a denaturation temperature of 94°C (1 min/cycle); an annealing 
temperature of 60°C for desmoplakin and 51°C for MPHOSPH 1(1 min/cycle); and an 
extension temperature of 72°C (1 min/1kb). The PCR products were analyzed by agarose gel 
electrophoresis. GAPDH was used as Housekeeping gene, and Testis cDNA as DNA positive 
control. 
4.5. Electrophoresis procedure 
The electrophoresis chamber was filled with (1x TAE) buffer. Each PCR-product was mixed 
with blue marker 5:1 (i.e. 10 µl PCR product + 2 µl marker) in a clean Eppendorf tube. The 
rest of the PCR product was stored at 2-8ºC until use. Each mixture was pipetted into one of 
the 1% agarose-gel cups. In the first cup, 10 µl of DNA marker VIII (Roche, Germany) was 
added. The agarose-gel was placed in the electrophoresis-chamber and the electrophoresis 
was performed using 400 mA, 100V for 45 min. After that, the agarose-gel was exposed to 
UV-light (UV-photo documentation) to visualize the products. 
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5. Study of antibody levels in the sera of PNH patients and 
controls  
5.1. Generation of MPHOSPH 1 expression construct 
5.1.1. Amplification of MPHOSPH 1 construct with PCR 
MPHOSPH1 cDNA was amplified from isolated phages using PCR with the following 
primers: forward primer (5`- GATATCATGCACAGCATATTCACTGTTAAA -3`) and 
reverse primmer (5`- GATATCACTTTGAAAATAGTGAGTCAGAAA -3`) 
Both primers were diluted with appropriate volume of distilled water to get the concentration 
of 100 pmol/ µl, after that they were mixed 1:1 and stored at -20 ºC until use. This stock 
solution was diluted 1:10 with distilled water when used. The following PCR components 
were mixed in an Eppendorf: 0.5 µl DNA (isolated phages), 2 µl primers mix, 0.2 µl dNTPs, 
3 µl Taq buffer, 0.2 µl Taq polymerase and 24.5 µl distilled water. 0.5 µl water was used 
instead of DNA as negative control, the amplification was performed using the program 
showed in table 6: 
Table 6: PCR program used to amplify MPHOSPH1 cDNA. 
 Time (min: sec) Temperature (ºC) Cycle number 
Hot start 12:00 94 1 
Denaturation 01:00 94  
35 Annealing 01:00 51 
Extension 01:00 72 
Final extension 9:00 72 1 
After amplification, the DNA product was mixed with blue marker and separated according to 
the molecular weight using gel electrophoresis on 1% agarose gel for 45 minutes. The next 
step was to detect the products using ultra violet light source and by comparing with the used 
DNA-marker VIII the position of MPHOSPH1 band was determined (~ 300 bp). 
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5.1.2. DNA cloning with TA vector 
The plasmid vector pCRII-TOPO (Invitrogen, Karlsruhe, Germany) was used for the first step 
of cloning. Because the vector is supplied linearized and contains single 3´-thymidine (T) 
overhangs for TA Cloning and topoisomerase I covalently bound to the vector, the PCR 
product amplified with Taq polymerase could be cloned directly. In an Eppendorf, 0.5 µl PCR 
product was added to 1 µl salt solution, 0.5 µl vector and 3 µl distilled water. It was mixed 
gently and incubated for 5 minutes at room temperature (22-23°C). After the incubation time, 
the reaction was placed on ice.  
5.1.3. Transformation into DH5α bacteria 
Transformation of the cloned product leads to a multiplication of the product depending on 
the multiplication of the bacteria. Transforming into DH5α (Invitrogen, Karlsruhe, Germany) 
was done using the manufactures guidelines as following: 2 µl of the TOPO cloning reaction 
was added into a vial of (1 µl) DH5α and mixed gently. The mixture was incubated on ice for 
5 to 30 minutes. After that, the cells were exposed to Heat-shock for 30 seconds at 42°C 
without shaking. The tubes were immediately transferred onto ice and kept stay for 5 minutes. 
10- 50 µl of cells were spread on a pre-warmed LB plate containing 50-100 µg/ml ampicillin 
and incubated overnight at 37°C.  
5.1.4. Analysis of Positive Clones  
Tens Miniprep protocol (GE Healthcare, Munich, Germany) was used to isolate the plasmid 
DNA from DH5α; the following materials are necessary for the isolation:  
TENS Buffer 
10 mM Tris-HCl pH 8.0 
1 mM EDTA pH 8.0 
0.1 N NaOH 
0.5% SDS 
TE pH 8.0 
10 mM Tris-HCl pH 8.0 
1 mM EDTA pH 8.0 
95%  EtOH  precooled to -20 º C 
70%  EtOH precooled to -20 º C  
3 M  Na Acetate pH 5.2 
RNAse A  
  
52 
 
 
The isolation was done using the manufactures guidelines: 2-6 colonies were taken and 
cultured overnight in 4 ml LB medium containing 50 µg/ ml ampicillin.1.5 mL of culture was 
centrifuged at 14.000 rpm for 1 min and the supernatant was removed. To the Pellet, 20 ug/ml 
RNase A was added and vortexed for 5 seconds. After that, 300 µl of TENS was added and 
vortexed for 5 seconds. After adding 150 µl of 3M NaOAc pH 5.2 and well mixing, a white 
precipitate was formed. The supernatant was transferred by pouring into a fresh tube and 
washed with 1 ml 95% EtOH and spined at 14 krpm for 1 minute. The supernatant was 
removed. The pellet was washed with 1 ml 70% EtOH and dried in air for 5-10 minutes at 
RT. After that, it was resuspended in 30 µl distilled water. 
In an Eppendorf, 2 µl DNA was mixed with 4 µl 10X Tango buffer (Fermentas GmbH, St. 
Leon-Rot. Germany), 0.5 µl enzyme (Eco RI) and 13.7 µl distilled H2O. The mixture was 
incubated at 37°C for 60 min, and then run on 2% agarose 1xTAE gel to determine the clones 
containing the required inserts. 
5.1.5. Cloning with pSFiExpress-HA 
MPHOSPH1 insert was subcloned in frame into pSfi-Express-HA vector (Fig 20) for His-tag 
fusion protein. pSfi-Express-HA vector is a derivative of pEGFP-C1 vector (Takara Bio 
Europe, Saint-Germain-en-Laye, France), the plasmid has a neomycin resistance gene for 
selection in mammalian cells. At first, both insert and vector were digested with SMAI restrict 
Enzyme (Fermentas GmbH, St. Leon-Rot. Germany). The digestion was done as following: 
In an Eppendorf; 5 µl Insert or 1 µl vector, 5 µl 10X buffer (tango), 0.5 µl BSA, 39.5 µl 
distilled H2O and 0.5 µl enzyme SMAI were mixed well. 
The mixture was incubated at 37°C for 120 min and run on 2% agarose 1xTAE gel. Two 
bands could be identified. The first band was about 2000 bp, which referred to the vector, and 
the second band was about 300 bp for MPHOSPH1-DNA. 
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Figure 20: A schematic representation of pSfi-Express-HA vector. 
5.1.6. DNA purification from Gel Band 
GFX PCR DNA and Gel Band purification kit (GE Healthcare / Germany) was used to purify 
the construct from agarose gel, the kit uses a chaotropic agent that denatures protein, dissolves 
protein, and promotes the binding of double- stranded DNA to a glass fiber matrix. Once the 
DNA is captured, protein and salt contaminants are washed away, and the purified DNA is 
eluted in a low ionic strength buffer (TE, Tris-HCl or water). The following components were 
included in this kit: 
Capture buffer Buffered solution containing acetate and 
chaotrop 
GFX columns MicroSpin columns pre- packed with a glass 
fiber matrix. 
Collection tubes 2 mL capless microcentrifuge tube. 
Wash buffer Tris-EDTA buffer ( 10 mM Tris-HCl pH 8.0, 
1 mM EDTA). Add absolute ethanol to a final 
concentration of 80 % before use. 
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The following reagents were necessary and not supplied in the Kit: absolute ethanol and 
Elution buffer: 10 mM Tris-HCl, pH 8.0, 1 mM EDTA or TE buffer (10 mM Tris-HCl pH 
8.0, 1 mM EDTA). 
The following equipments were necessary for the purification: 
- Microcentrifuge: that accommodates 1.5 ml microcentrifuge tubes. 
- Tubes: 1.5 ml microcentrifuge tubes.  
- Scalpel or razor blade. 
- Incubator or water bath / 60º C. 
The purification was done according to the manufacturer’s instructions as follows: an empty 
1.5 ml microcentrifuge tube was weighed and the weight was recorded. Using a clean razor 
blade or scalpel, the slice of agarose containing the DNA band was excised to be purified and 
the slice was cut into several smaller pieces then transferred them to the pre-weighted 1.5 ml 
microcentrifuge tube. The tube was weighed again and the weight of the slice was determined 
by subtracting the weight of the empty tube. Then, 10 µl of capture buffer was added to each 
10 mg of gel slice (maximum column capacity is 300 µl of capture buffer added to 300 mg gel 
slice). After closing the tube, the content was mixed by vortexing vigorously and incubated at 
60º C until the agarose is completely dissolved (5-15 min). One GFX column for each tube 
was placed, during the incubation in a collection tube. After the agarose had been completely 
dissolved, it was briefly centrifuged to collect the sample at the bottom of the tube. The 
sample was transferred to the GFX column and incubated at room temperature for 1 min. 
After that it was centrifuged in a microcentrifuge at full speed for 30 s, the flow-through was 
discarded by emptying the collection tube, and the GFX column was placed back inside the 
collection tube. The DNA was washed by adding 500 µl of wash buffer to the column and it 
was centrifuged at full speed for 30 s. The collection tube was discarded and the GFX column 
was transferred to a fresh 1.5 ml microcentrifuge tube. After that, a 10µl double distilled was 
applied water directly to the top of the glass fiber matrix (in the GFX column) and incubated 
the sample at room temperature for 1 min. To recover the purified DNA, the tube with column 
was centrifuged at full speed for 1 min then it proceeded to ligation step.  
For the cloning of MPHOSPH1-DNA with pSfi-Express-HA vector, the following reagents 
were placed into a 1.5 ml tube: 2 µl DNA + 10 µl ligase buffer + 1 µl pSfi-Express-HA 
vector + 2 µl DNA ligase.   
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The DNA-ligase enzyme ligates then the two cleaved ends of the vector. The ligation step was 
done at 16 ºC over night. 
Transformation and miniprep were done as mentioned above. (See paragraph 5.1.4)    
5.1.7. Digestion with enzymes 
In order to determine which of the colonies contains the MPHOSPH1-DNA fragment, the 
fragments were digested using appropriate restriction enzymes. Using the NEBcutter V2.0 
website (http://tools.neb.com/NEBcutter2/index.php), the enzymes that do not cut 
MPHOSPH1 sequence was selected. 
Two enzymes were used here because using one enzyme will cleave the vector in one site, 
leading to a linear DNA with almost the same size. When two enzymes are used, the vector is 
cleaved in two different sites into two pieces. These two DNA fragment differ in size 
depending on whether the vector include the insert or not. 
Two different enzymes (Hind III and NdeI) were incubated for 60 min at 37ºC with the 
extracted DNA product from the last step. The following materials were used for this step: 1µl 
BglII, 1µl EcoRI, 2 µl Orange buffer, 0.5µl BSA, 3 µl DNA (from miniprep), 10.5 µl H2O. 
The products were then mixed with blue marker and an electrophoresis on 2% agarose gel 
was performed. According to the molecular weight of the bands viewed by UV-light, the 
colony, which contained the proper DNA fragment, could be determined. 
5.1.8. Preparation of Midi preps 
QIAGEN Plasmid Midi kit (QIAGEN- Dusseldorf, Germany) was used in order to gather 
enough plasmid DNA for transfection. The procedure was done according to manufacturer’s 
guidelines as follows:  
1- 500 µl from miniprep culture was inoculated into 100 ml LB-medium containing 50 µg/ µl, 
and grown at 37 ºC for 14 hours with vigorous shaking (~ 250 rpm).  
2- The cells were divided into two 50 ml tubes and harvested by centrifugation at 4500 X g 
for 20 min.  
3- Each bacterial pellet was resuspended in 10 ml buffer P1 (Resuspension buffer) 
  Buffer P1: 50 mM Tris·Cl, pH 8.0, 10 mM EDTA, 100 µg/ml RNase A. 
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4- 10 ml buffer P2 (lysis buffer) was added to each tube, mixed gently by inverting 4 - 6 
times. Buffer P2: 200 mM NaOH, 1% SDS (w/v). 
5- 10 ml buffer P3 (neutralization buffer) was added to each tube. The contents were mixed 
by gently inverting 4-6 times and put on ice for 15 min. Buffer P3: 3.0 M potassium acetate 
(PH 5.0). 
6- After centrifugation at ≥ 20,000 g for 30 min at 4 ºC, the supernatant containing plasmid 
DNA was removed promptly.   
7- The supernatant was centrifuged again at ≥ 20,000 g for 15 min (4ºC) and the supernatant 
containing plasmid DNA was removed promptly. 
8- A QIAGEN-tip 100 was equilibrated by applying 4 ml Buffer QBT (equilibration buffer), 
and the column was allowed to empty by gravity flow. Buffer QBT: 750 mM NaCl, 50 mM 
MOPS, pH 7.0, 15% isopropanol (v/v), 0.15% Triton X-100 (v/v). 
9- The two supernatants from step 7 were pooled and the sample was applied to the two 
QIAEN-tip and allowed to enter the resin by gravity flow. 
10- The QIAGEN-tip was washed with 2x10 ml buffer QC (wash buffer). Buffer QC: 1.0 M 
NaCl, 50 mM MOPS, pH 7.0, 15% isopropanol (v/v). 
11- DNA was eluted with 5x1 ml Pre-warmed to 65 4 ºC buffer QF (elution buffer). Buffer 
QF: 1.25 M NaCl, 50 mM Tris·Cl, pH 8.5, 15% isopropanol (v/v). 
12- DNA was precipitated by adding 3.5 ml room-temperature isopropanol, mixed and 
centrifuged immediately at ≥ 15,000 x g for 30 min at 4 ºC. The supernatant was decanted 
carefully. 
13- The DNA pellet was washed with 2 ml of room-temperature 70 % ethanol and centrifuged 
at ≥ 15,000 x g for 10 min. The supernatant was carefully decanted without disturbing the 
pellet. 
14- After air-drying the pellet for 5-10 min, the DNA was dissolved in a 20 µl distilled water 
and the concentration was determined. 
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5.1.9. HEK 293 Cell Transfection and cell culture 
HEK 293 cell line (Takara Bio Europe, Saint-Germain-en-Laye, France) was used for 
transfection and protein expression. HEK 293 cells were generated by transformation of 
human embryonic kidney cell cultures (hence HEK) with sheared adenovirus 5 DNA, and 
were first described in 1977. 
Thawing of the cells  
Cells were stored in liquid nitrogen, RPMI medium was added to dilute the toxic freezing 
medium dimethylsulfoxid (DMSO) and the cells were thawed in a water bath at 37ºC, then 
centrifuged at 3000 x g for 5 min. After that, the supernatant was disposed and the cells were 
resuspensed in a 750 ml flask filled with 500 ml medium and incubated at 37º C with 5% 
CO2. The cover of the culture bottles was not tightly closed to allow CO2 and humidity to 
enter the flask. Maintenance of the cells was performed twice a week with growth and 
maintenance medium (1:10) and then incubated at 37ºC with 5% CO2. 
Cell transfection  
Transfection of HEK 293 cells with pSfi-Express-HA vector containing MPHOSPH1 insert 
was done using FuGENE HD transfection reagent (Roche Applied science, Mannheim, 
Germany), the transfection was done following the manufacturer’s guidelines as follows:  
The plasmid DNA solution was prepared in sterile water at a concentration of 0.1 µg/ µl. For 
initial optimization experiments, a monolayer of cells that is 80 – 90% confluent was 
transfected in a six-well culture dish, using 3:2, 4:2, 5:2, 6:2, 7:2, and 8:2 ratios of FuGENE 
HD Transfection Reagent (µl) to DNA(µg), respectively. FuGENE HD Transfection Reagent, 
DNA, and diluent were allowed to adjust to +15 to +25°C. 100 µl diluents, containing 2 µg 
DNA, was Placed into each of six sterile tubes labeled 3:2, 4:2, 5:2, 6:2, 7:2, and 8:2. The 
FuGENE HD Transfection Reagents (3, 4, 5, 6, 7, or 8 µl) were directly transferred into the 
medium containing the diluted DNA without allowing contact with the walls of the plastic 
tubes. The tubes were vortexed for one to two seconds to mix the contents and the mixture 
was incubated for 15 minutes at room temperature. The transfection complex was added to the 
cells in a drop-wise manner. The wells were swirled to ensure distribution over the entire 
plate surface. After transfection, the cells were incubated for 18 – 72 hours prior to measuring 
the protein expression. After this incubation period, the protein expression was measured 
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using western blot analysis. Western blot analysis was applied to confirm size and specificity 
of the protein using a mouse anti-His monoclonal antibody (1:3000; Sigma, St Louis, MO) 
and a MPHOSPH1-specific mouse polyclonal antibody (1: 500; Abnova, Taiwan). 
5.1.10. Western blot analysis  
Purified proteins were prepared in sodium dodecyl sulfate (SDS) sample buffer. Equal 
amounts of protein were analyzed by SDS polyacrylamide gel electrophoresis (PAGE), 
transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA), and 
incubated with blocking buffer overnight. Immunoblots were performed at 1:500 dilution of 
patients’ serum, mouse anti-His monoclonal antibody or MPHOSPH1-specific mouse 
polyclonal antibody, respectively. Immunodetection was performed by incubation with 
horseradish peroxidase-conjugated antihuman IgG (1:10.000) or anti-mouse IgG secondary 
antibody (1:5000) as indicated by the host origin of the primary antibody and developed by 
chemiluminescence (NEN Life Science Products, Boston, MA).  
5.2. Generation of desmoplakin expression construct 
5.2.1. Amplification of desmoplakin construct with PCR 
Amplification of desmoplakin cDNA was done using the following primers, as forward 
primer (5’-GGCTTCGAGGGTGTGAAGGGAAAGAA-3’) and reverse primer (5‘- 
TGCGGTGTCCCTTAAGAAGGATGA -3‘) with annealing temperature of 60 ºC.   
Both primers were diluted with appropriate volume of distilled water to get the concentration 
of 100 pmol/µl, mixed 1:1 and stored at -20ºC until use. Before use, this stock solution was 
diluted 1:10 with distilled water. 
The following PCR reaction components were applied: 2 µl Primers mix, 0.2 µl DNTPs, 3 µl 
Buffer Taq 10x, 0.2 µl Taq polymerase, 24.5 µl H2O and 0.5 µl DNA. 
As negative control, 0.5 µl water instead of DNA was used, the amplification was performed 
using a PCR-program described in table 7: 
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Table 7: PCR-program used for amplification of desmoplakin construct. 
 Time (min: sec) Temperature (ºC) Cycle number 
Hot start 12:00 94 1 
Denaturation 01:00 94  
35 Annealing 02:00 60 
Extension 01:00 72 
Final extension 9:00 72 1 
After amplification, the DNA product was mixed with blue marker. Using 1 % agarose gel, 
the DNA was separated according to the molecular weight for 45 minutes. The next step was 
to detect the products using ultra violet light source and by comparing with DNA-marker 
VIII, the position of desmoplakin band could be determined (~ 2 Kbp). 
5.2.2. DNA cloning with pSectag/FRT/V5-His topo TA Expression vector 
pSectag/ FRT/V5-His topo TA Expression vector (Invitrogen- Germany) was used for the 
cloning (Figures 21 and 22). In an Eppendorf 0.5 µl PCR product was added to 1 µl salt 
solution, 0.5 µl Topo vector and 3 µl distilled Water. Mixed the reaction gently and incubated 
for 5 minutes at room temperature (22-23°C). The mixture was placed on ice and continued to 
transforming competent cells. The product was tested with gel electrophoresis to determine 
the desmoplakin Band (~ 2000 bp). 
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Figure 21: Schematic presentation of pSecTag/FRT/V5-His-TOPO vector (5185 bp). 
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Figure 22: Sequence of the cloning sites of pSectag/FRT/V5-His topo vector.  
5.2.3. Cell transfection with the vector 
On the day of transfection, HEK 293 cells were tested; the cell confluency has to be about 70-
80 %. For Transfection, FuGENE HD Transfection (Roche Applied science - Mannheim, 
Germany) was used. The transfection complex was done according to manufacturer’s 
instructions as follows: 
Five µg DNA was suspended in 100 µl RPMI medium, for transfection control, 5 µg green 
fluorescent protein (GFP) instead of DNA was used. After that, 7.5 µl FuGENE were added 
carefully according to transfection ratio (DNA/FuGENE = 2/3), mixed gently and stored 15 
minutes at room temperature. The transfection mixture was then added to the cells growing in 
2 mL RPMI Medium 1640  medium (Invitrogen- Germany) with 10 % v/v  fetal calf serum 
(FCS) and was grown at 37ºC with 5% CO2. After three days, the growing of the cells was 
tested and 1 mg/ml Geneticin G 418 sulfate (which is an aminoglycoside antibiotic similar in 
structure to gentamicin B1) was added. 
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Western blot analysis was applied using a mouse anti-His monoclonal antibody (1:3000; 
Sigma, St Louis, MO, USA) and desmoplakin 1&2 mouse monoclonal antibody (1:2000, 
Biotechnica, Germany) as described by MPHOSPH1. 
5.3. Titration of antibodies by ELISA  
In order to determine the titers of antibodies against the two gene products in the sera of PNH 
patients and healthy controls; sera were tested for reactivity against desmoplakin and 
MPHOSPH1 by ELISA. Plates were coated with mouse anti MPHOSPH1 antibody for 
MPHOSPH1 and rabbit anti mouse antibody followed by mouse anti-desmoplakin antibody 
for desmoplakin (Figure 23).  
 
Elisa for MPHOSPH 1 
 
Elisa for Desmoplakin 
Figure 23: ELISA system for desmoplakin and MPHOSPH1. 
Plates were washed with PBS and blocked overnight at + 4°C with 5% nonfat dry milk in 
TBST. After washing the plates with PBS, 100 µl 1:1 cell lysate were added to each well and 
incubated at 37º C for two hours. Using PBS, the plates were washed three times and patients’ 
sera were added to a final dilution of 1:1000 and incubated at room temperature for 2 hours. 
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After washing, the plates were incubated with alkaline phosphatase-conjugated goat 
antihuman IgG antibody (1:7500; Promega) at room temperature. Finally, the plates were 
washed and incubated with p-nitrophenyl phosphate (PNPP) substrate (Pierce, Rockford, IL) 
at room temperature, and the optic density (OD) at 405 nm was determined. A positive 
reaction was defined as an absorbance value exceeding the mean OD absorbance value of sera 
from healthy donors by three standard deviations. 
6. Epitope mapping 
In order to detect hot spots of epitopes recognized by anti-desmoplakin antibodies and anti-
MPHOSPH1 of different patients, epitope mapping was performed using PCR with different 
primers that amplify small fragments (~ 200 bp) . After amplification, fragments were ligated 
individually into pSectag/FRT/V5-His topo TA expression vector (Invitrogen- Germany). 
Using FuGENE HD Transfection (Roche Applied science - Mannheim, Germany); HEK293 
cells were transformed with each of the constructed pSectag/FRT/V5-His topo TA Vector for 
peptide expression. An ELISA system was established by coating wells with anti-HIS 
antibodies followed by cell lysates from each of the culture mentioned above. After washing, 
patients’ sera, that showed reactivity against desmoplakin and MPHOSPH1, were added. 
After that, plates were incubated with alkaline phosphatase-conjugated goat antihuman IgG 
antibody (1:7500; Promega) at room temperature. Finally, the plates were washed and 
incubated with p-nitrophenyl phosphate (PNPP) substrate (Pierce, Rockford, IL) at room 
temperature, and the optic density (OD) at 405 nm was determined. 
7. Construction of cDNA Library from CD34+ Cells 
7.1. CD34+ cells Isolation 
400 ml peripheral blood with EDTA was used from normal individual to isolate CD34+ cells. 
The selection was done using CD34 MicroBead Kit (Miltenyi Biotec, Germany). The 
following steps were done according to the manufacturer’s instructions: 
7.1.1. Isolation of peripheral blood mononuclear cells (PBMCs) using Ficoll-
paque 
The cells were diluted with four volumes of phosphate buffer saline (PH 7.2) supplemented 
with 2 mM EDTA. Over 15 ml Ficoll-Paque (GE Healthcare companies, Germany) 35 mL of 
diluted cell suspension was layer carefully in a 50 mL conical tube and centrifuged at 400xg 
for 40 minutes at 20 °C in a swinging bucket rotor without brake. After that, the upper layer 
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was aspirated leaving the mononuclear cell layer undisturbed at the interphase. The interphase 
contains lymphocytes, monocytes and thrombocytes. The interphase was transferred into a 
new 50 mL conical tube. The tube was filled with PBS containing 2 mM EDTA, mixed and 
centrifuged at 300 xg for 10 minutes at +20°C and the supernatant was removed completely. 
In order to remove the platelets, the cell pellet was resuspended in 50 mL of buffer, 
centrifuged at 200 xg for 15 minutes at +20 °C and the supernatant was removed completely. 
In order to remove the platelets completely, the last step was repeated. The cell pellet was 
resuspended in a final volume of 300 µL of buffer and stored in +4 °C for use.  
7.1.2. Magnetic labeling and separation 
The magnetic labeling and separation was made using the protocol mentioned above (see 
4.1.2 and 4.1.3). After separation, cells were counted using a Neubauer counting chamber. 
The purity of CD34+ cells was tested using flow cytometry. 
7.2. Extraction of mRNA 
7.2.1. Extraction of total RNA 
RNeasy Mini kit (Qiagen, Germany) was used to extract total RNA from the selected cells. 
Before starting, the reagents provided by the kit were prepared: 
10 µl β-mercaptoethanol (β-ME) was added to 1 ml RLT buffer. The buffer RPE was supplied 
as a concentrate, so that 4 volumes of 100% ethanol were added to make the working 
solution. RNA extraction was done according to the manufacture’s guidelines as follows: 
1. The cell suspension was centrifuged for 5 min at 300 xg and the supernatant was removed 
carefully, the cells were disrupted by flicking the tube and adding 350 µl buffer RLT, mixed 
well by vortexing and proceeded to the next step. 
2. The lysate was pipeted into a QIAshredder spin column placed into a 2 ml collection tube, 
centrifuged for 2 min at full speed. After that, one volume of 70 % ethanol was added to the 
homogenized lysate and mixed well by pipetting. 
3. Up to 700 µl of the sample was transferred to an RNeasy spin column placed into a 2 ml 
collection tube, the lid was closed, centrifuged for 15 seconds at ≥ 8000 g (≥10.000 rpm) and 
the flow-through was discarded. 
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4. 700 µl buffer RW1 was added to the RNeasy spin column, the lid was closed, centrifuged 
for 15 seconds at ≥ 8000 g (≥10.000 rpm) to wash the spin column membrane, and the flow-
through was discarded. 
5. 500 µl buffer RPE was added to the column, the lid was closed, centrifuged for 15 seconds 
at ≥ 8000 g (≥10.000 rpm) and the flow-through was discarded. 500 µl Buffer RPE was added 
again to the column, the lid was closed, centrifuged for 2 min at ≥ 8000 g (≥10.000 rpm) and 
the flow-through was discarded. 
6. The RNeasy spin column was placed into a new 1.5 mL collection tube, 40 µl RNase-free 
water was added directly to the column membrane, the lid was closed and centrifuged for 1 
min at ≥ 8000 g (≥10.000 rpm) to elute the RNA. Step 6 was repeated using another 40 µl 
RNase-free water in order to have the required amount, which was 90 µg total RNA. 
7.2.2. Purification of mRNA 
For the purification of mRNA, Dynabeads Purification Kit (Invitrogen, Germany) was used. 
The isolation of mRNA relies on base pairing between the poly A residues at the 3’ end of 
most mRNA and the oligo (dT) 25 residues covalently coupled to the surface the surface of the 
Dynabeads. Other RNA species lacking a poly A tail will not hybridize to the beads and are 
readily washed away. The following buffers were provided: Binding Buffer (20 mM Tris-HCl 
{pH 7.5}, 1.0 M LiCl, 2 mM EDTA), Washing Buffer B (10 mM Tris-HCl {pH 7.5}, 0.15 M 
LiCl, 1 mM EDTA), and 10 mM Tris-HCl (pH 7.5). 
Purification of mRNA was done according to the following steps: 
1. The volume of total RNA to100 µl was adjusted with 10 mM Tris-HCl, heated to 65°C for 
2 minutes to disrupt the secondary structures and it was finally placed on ice.  
2. As a next step, 200 µl of resuspended Dynabeads were transferred from the stock tube 
suspension, dispensed into a 1.5 ml microcentrifuge tube, and placed on the magnet. After 30 
seconds, the supernatant was pipetted off, the tube was removed from the magnet, the 
Dynabeads were resuspended in 100 µl binding buffer, and the tube was placed back on the 
magnet. After 30 seconds, the supernatant was pipeted off and the tube was removed from the 
magnet. 
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3. 100 µL binding buffer was added to the Dynabeads. The total RNA was added to the 100 
µL Dynabeads/Binding Buffer suspension, mixed thoroughly and rotated on a roller for 3–5 
minutes at room temperature to allow mRNA to anneal to the oligo (dT) 25 on the beads. 
4. The tube was placed on the magnet until solution became clear, the supernatant was 
removed, the tube was removed from the magnet, and the mRNA-bead complex were washed 
twice with 200 µl Washing Buffer B. The mRNA was eluted using 15 µL mM tris-HCl and the 
eluted mRNA was transferred to a new RNase-free Tube. 
7.3. First-Strand cDNA synthesis 
For this step, a switching mechanism at 5’ end of RNA transcript (SMART) cDNA Library 
Construction Kit (Takara Bio Europe, Saint-Germain-en-Laye, France) was used. The 
following components were necessary: 
• SMART IV Oligonucleotide ( 12 µM) 
5´-AAGCAGTGGTATCAACGCAGAGTGGCCATTACGGCCGGG-3` 
• CDS III/ 3`PCR primer (12 µM) 
5`-ATTCTAGAGGCCGAGGCGCCGACATG-d(T)30N_1N-3` 
(N=A, G, C, or T; N_1= A, G, or C) 
• SMARTScribe MMLV Reverse Transcriptase (100 units /µL) 
• 5X First-Strand Buffer, which consist of the following ingredients: 
250 mM Tris (pH 8.3) 
30 mM MgCl2 
375 mM KCL 
• DTT (dithiotreitol;20 mM) 
• Control poly A+ RNA (Human Placenta; 1.0 µg/ µL) 
• DNA size markers 
• 1.1% Agarose/EtBr gel (containing 0.1 µg/mL ethidium bromide) 
The CDS III/ 3`PCR primer is a modified oligo (dT) primer, which primes the first-strand 
synthesis reaction, and the SMART IV Oligo serves as a short extended template at the 5’ end 
of the mRNA. When the reverse transcriptase (RT) reaches the 5’ end, the enzyme’s terminal 
transferase activity adds a few additional nucleotides, primarily deoxycytidine, to the 3’ end 
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of the cDNA. The SMART IV Oligo, which has an oligo (G) sequence at its 3’ end, base-pairs 
with the deoxycytidine stretch, creating an extended template. RT switches the templates and 
continues replacing to the end of the Oligonucleotide. The resulting full-length single strand 
cDNA contains the complete 5’ end of the mRNA, as well as the sequence complementary to 
the SMART IV Oligo, which then serves as a universal priming site (SMART anchor) in the 
subsequent amplification by long distance PCR. According to the manufacture’s guidelines 
the following steps were done: 
In a sterile 0.5-mL microcentrifuge tube, the following reagents were combined: 1 µL RNA 
sample (or 1 µL control RNA for the control) + 1 µL SMART IV Oligonucleotide + 1 µL 
CDS III/3’ PCR primer. A total volume up to 5 µL was obtained using deionized H2O. The 
contents were mixed and the tube spun briefly in a microcentrifuge. The tube was incubated at 
72 °C for 2min. The tube was cooled on ice for 2 minutes; the contents were collected at the 
bottom of the tube by briefly spun. The following contents were added to the tube: 
2.0 µL First Strand Buffer 
1.0 µL DTT (20 mM) 
1.0 µL dNTP Mix (10mM) 
1.0 µL SMARTScribe MMLV Reverse Transcriptase 
The contents were mixed by gently pipetting and were briefly centrifuged. The tube was 
incubated at 42 °C for 1 hour using a hot lid thermal cycler. After the incubation, the tube was 
placed on ice in order to terminate first-Strand synthesis. 2 µL from the mixture for PCR step 
was put in a clean 0.5-mL tube, and the tube was placed on ice. The rest of mixture was stored 
at -20 °C. 
7.4. Amplification of cDNA by PCR 
For the amplification is a 5’ PCR Primer necessary, the primer has the following sequence: 
5’-AAGCAGTGGTATCAACGCAGAGT-3’  
The Advantage 2 Polymerase Mix is used, which is a mix of TITANIUM Taq DNA 
polymerase (Takara Bio Europe, Saint-Germain-en-Laye, France) - a nuclease- deficient N-
terminal deletion of Taq DNA polymerase plus Start Antibody to provide automatic hot-start 
PCR- and a minor amount of proof reading polymerase. This system allows to amplify 
68 
 
 
efficiently full-length cDNA with a fidelity rate significantly higher than that of conventional 
PCR.  
The PCR thermal cycler was preheated to 95 °C and the following components were added to 
the reaction tube: 
2 µL first-strand cDNA 
80 µL deionized H2O 
10 µL 10x PCR buffer 
2 µL  50x dNTP mix 
2 µL 5’ PCR primer 
2 µL CDS III/3’ PCR primer 
2 µL 50x Advantage 2 Polymerase Mix  
The contents were mixed by flicking the tube gently and the contents were collected at the 
bottom of the tube by briefly centrifugation. The tube was placed in a preheated thermal 
cycler. The amplification was done at annealing temperature of 68 °C for 6 min and 25 PCR 
cycles. 
After the completion of the cycling, 5 µL of the PCR product was analyzed alongside 0.1 µg 
of 1-kb DNA size markers, on a 1.1 % agarose/EtBr gel.  
7.5. Proteinase K digestion 
Digestion proteinase K (20 µg/µL) was used for this step. In a sterile 0.5-mL tube, 50 µl of 
amplified ds cDNA and 2 µL of proteinase K were mixed, and the tube was spun briefly. The 
mixture was incubated at 45 °C for 20 min, the tube spun briefly. 50 µl of deionized H2O and 
100 µL of phenol:chloroform:isoamyl alcohol were added to the tube and mixed by 
continuous gentle inversion for 2 minutes. The phases were separated by centrifugation at 
14.000 rpm for 5 min. The top layer was moved to a clean 0.5-ml tube and the rest was 
discarded. To the aqueous layer, the following solutions were added: 10 µl of 3 m sodium 
acetate, 1.3 µl of glycogen (20 µg/µL) and 260 µL of room temperature 95% ethanol. Then, it 
was centrifuged at 14.000 rpm for 5 min and the phases were separated. The supernatant was 
removed, without disturbing the pellet, using a pipette. After that, the pellet was washed with 
100 µl of 80% ethanol and air dried for 10 min. 79 µL of deionized H2O was added to 
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resuspend the pellet. 
7.6. Sfi L digestion 
Sfi L enzyme was used for the digestion because its asymmetrical restriction sites at the 5’ and 
3’ cDNA ends, the recognition sequences of both SfilA and SfilB is shown in table 8: 
Table 8: The recognition sites of SfilA and SfilB enzymes. 
Sfi L A site Sfi L B site 
 
5’-GGCCATTACGGCC-3’ 
3’-CCGGTAATGCCGG-5’ 
 
5’ – GGCCGCCTCGGCC – 3’ 
3’ – CCGGCGGAGCCGG – 5‘ 
For this step, the following components were used: Sfi LEnzyme (20 units/µL), 10x Sfi L 
buffer, 100x BSA.  
In a fresh 0.5-ml tube, 79 µL cDNA, 10 µL 10x Sfi Buffer, 10 µL Sfi L enzyme and 1 µL 
100x BSA were combined, mixed well and incubated at 50 °C for 2 hours. Then 2 µL of 1 % 
xylene cyanol dye was added to the tube and mixed well. 
7.7. Size fractionation of cDNA by chroma SPIN-400 
Sixteen 1.5-ml tubes were labeled and arranged in a rack in order, then the CHROM Spin-400 
column (which is a spin column packed with gel filtration resin to rapidly purify and size 
select nucleic acid samples) were prepared for drop procedure. The column was inverted 
several times to resuspend the gel matrix completely. The air bubbles were removed from the 
column. The column was attached to a ring stand, and the storage buffer was drained through 
it by gravity flow, until the surface of the gel beads in the column matrix became visible. The 
top of the column matrix should be at 1.0-ml mark on the wall of the column and the flow rate 
should be approximately 1 drop/40-60 sec. After the storage buffer stopped dripping; 700 µL 
buffer was added to the top of the column and allow it to drain out. When this buffer stopped 
dripping (~ 15-20 min), 100 µl mixture of Sfil-digested cDNA and xylene cyanol dye was 
applied to the top-centre surface of the matrix. The sample was left to be absorbed by the 
surface of the matrix. 
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The tube, which contained the cDNA, was washed with 100 µL of column buffer and applied 
to the surface of the matrix. After the buffer dripped out the column, the rack containing the 
collection tubes was placed under the column, 600 µL of column buffer was added to the 
column, and single-drop fractions were immediately collected. In order to test the fractions, 
electrophoresis (at 150 V for 10 min) of 3 µl of each fraction on a 1.1 % agarose/EtBr gel 
alongside 0.1 µg of 1-kb DNA size marker should be made. The peak fractions were 
determined by visualizing the intensity of the bands under UV. The first three fractions 
containing cDNA were collected and pooled in a clean 1.5-ml tube. The following reagents 
were added to the tube containing cDNA fractions: 
1/10 vol Sodium Acetate (3M; pH 4.8) 
1.3 µl Glycogen (920 mg/ml) 
2.5 vol 95% ethanol (-20 °C) 
After mixing gently, the tube was placed in -20 °c for 1 hour, and then centrifuged at 14.000 
rpm for 20 min at room temperature. The supernatant was removed with a pipette without 
disturbing the pellet, the process was repeated, and the pellet was air dried for 10 min. The 
pellet was resuspended in 7 µL of deionized water and mixed gently. The Sfil-digested cDNA 
was ready to be ligated to the Sfil- digesed, diphosphorylated λ TripelEx2 vector.  
7.8. Ligation of cDNA to λ TriplEx2 vector  
The following protocol is optimized for ligation of SMART cDNA to the λ TriplEx2 DNA: A 
test ligation was made to determine the efficacy of ligating the vector to the control insert. 1 
µL of vector, 1 µL of control insert, 1.5 µL of deionized H2O, 0.5 µL 10xligation buffer, 0.5 
µL ATP (10 mM) and 0.5 µL T4 DNA Ligase were used. Ligation mixture was incubated at 
16 °C overnight. After that, a λ-phage packaging reaction was applied and the titers of the 
resulting phages were determined, the ligation was considered efficiency if ≥ 1x107 pfu/µg of 
input vector were obtained. In each of three 0.5-ml tubes, 1 µL of vector, 0.5 µL of cDNA, 2 
µL of deionized H2O, 0.5 µL 10xligation buffer, 0.5µL ATP (10 mM) and 0.5 µL T4 DNA 
ligase. The tubes were mixed gently without producing air bubbles, briefly centrifuged to 
bring contents to the bottom of the tubes. The tubes were incubated at 16 °C overnight. After 
that, a λ-phage packaging reaction was performed and the titer of the resulting phages for 
each of the ligations was determined. The unamplified libraries can be stored at 4 °C for 2 
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weeks. 
7.9. Bacterial culture plating 
First, the frozen cells of (E.coli XL1-Blue and BM.25) were recovered by streaking small 
portion (5µL) of the frozen stock onto an LB agar plate containing the appropriate antibiotic 
(LB agar with tetracycline for XL1-Blue stock plates and kanamycin) this was the primary 
streak plate. The LB agar was incubated at 37 °C overnight. After that, it was covered with 
parafilm and stored at 4 °C. A single isolated colony from the primary streak plate was picked 
and streaked onto another LB/MgSO4 agar plate without antibodies. The plate was incubated 
at 37 °C overnight. The plate was covered with parafilm and stored at 4 °C for two weeks. 
This plate is used as a source of fresh colonies for inoculating liquid cultures and preparing 
the next fresh working stock plate. At 2-weeks intervals, a fresh working stock plate was 
prepared from the previous working stock plate. 
7.10. Titration of unamplified library 
Determining the titer of the unamplified library gives an estimate of the number of 
independent phage and independent clones in the library, which helps to determine the 
efficiency of the ligation of vector to positive control insert and the background titer of the 
vector alone. The titration was made according to the following steps: 
1. A single, isolated colony from the working stock plate was picked and used to inoculate 15 
ml LB/MgSO4/ maltose broth in a 50-ml test tube or erlenmeyer flask. Then it  was incubated 
at 37 °C overnight while shaking (at 140 pm) until the OD600 of the culture reached (2.0).The 
cells were centrifuged at 5.000 rpm for 5 min, the supernatant was poured off, and the pellet 
was resuspended in 7.5 ml of 10 mM MgSO4. 
2. A number of 90-mm LB/MgSO4 plates were warmed and dried. 
3. Dilutions (1:5, 1:10, 1:15, and 1:20) of each of the packaging extracts (from 7.8) were 
made and the following steps for each dilutions of each extract were performed: 
1 µl of the diluted phage was added to 200 µL of the XL1-blue overnight culture and allowed 
the phage to adsorb at 37 °C for 10-15 min. 2 ml of melted LB/MgSO4 top agar was also 
added, mixed by quickly inverting and immediately poured onto 90-mm LB/MgSO4 plates 
prewarmed to 37 °C. The plates were swirled quickly after pouring to allow even distribution 
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of the top agar. The plates were cooled at room temperature for 10 min to allow the top agar 
to harden, inverted and incubated them at 37 °C for 16 hours. The number of the growing 
plaques was counted and the titer of the phage (pfu/ml) was calculated according to the 
following equation:  
Pfu/ml = number of plaques x dilution factor x 103 µL/ml 
µL of diluted phage plated 
By 1:1 vector: insert, 1x107 clones were obtained, which means that the ratio was optimal for 
the ligation. 
7.11. Determination of the percentage of recombinant clones 
To perform blue/white screening in E.coli XL1-Blue, the same procedure of titration an 
unamplified library was followed (Paragraph 7.10) except adding IPTG and X-gal to the 
melted top agar before plating the phage + bacteria mixtures. For every 2 ml of melted top 
agar, 50 µL of the IPTG and X-gal stock solutions were used. The plates were then incubated 
at 37 °C until plaques and blue color developed (~14 hours). The ratio of white (recombinant) 
to blue (non-recombinant) plaques gives a quick estimate of recombination efficiency.   
7.12. Library amplification 
1. A single, isolated colony from the primary working plate of XL1-Blue was picked and used 
to inoculate 15 ml LB/MgSO4/ maltose broth. The culture was incubated at 37 °C overnight 
while shaking (at 140 pm) until the OD600 of the culture reached (2.0). The cells were 
centrifuged at 5.000 rpm for 5 min, the supernatant was poured of, and the pellet was 
resuspended in 7.5 ml of 10 mM MgSO4. 
2. A number of 90-mm LB/MgSO4 plates were warmed and dried. 
3. The required number of 4-ml tubes with 500 µL of overnight bacterial culture and enough 
diluted lysate were added to have 6-7x104. The mixture was incubated in a 37 °C water bath 
for 15 min. After that, 4.5 ml of melted LB/MgSO4 soft-top agar was added to each tube. 
4. The mixture of bacteria and phages was poured onto LB/MgSO4 agar plates. 
5. The plates were swirled quickly after pouring to allow even distribution of the top agar.  
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The plates were cooled at room temperature for 10 min to allow the top agar to harden, then 
they were inverted and incubated at 37 °C for 16 hours.  
6. To each plate, 12 ml of 1xlambda dilution buffer was added, stored at 4 °C overnight. The 
plates were put on platform shaker (~ 50 rpm), the plates were incubated at room temperature 
for 1 hour. The λ-phage lysate was poured into a sterile beaker.  
7. To clear the phage lysate of cell debris and to lyse any remaining intact cells, the phage 
lysate was mixed well and poured into a sterile, 50-ml polypropylene, screw-cap tube. 10 ml 
of chloroform was added to the lysate, screw on the cap and vortexed for 2 min, centrifuged at 
7.00 rpm, and collected the supernatant into another sterile 50-ml tube. The cap was tightly 
closed and place at 4 °C. The amplified library can be stored at 4 °C for up to 6 months. For 
long-term storage; 1-ml aliquots were made, DMSO was added to a final concentration of 7 % 
and placed at -70 °C. 
7.13. Titration of the amplified library 
The same procedure that used in the titration of an unamplified library was used as follows: 
1. A single, isolated colony from the primary working plate of XL1-Blue was picked and used 
to inoculate 20 ml LB/MgSO4/ maltose broth (without antibiotic). After that, it was incubated 
at 37 °C overnight while shaking (at 140 rpm) until the OD600 of the culture reached (2.0). 
The cells suspension was centrifuged at 5.000 rpm for 5 min, poured of the supernatant, and 
resuspended the pellet in 7.5 ml of 10 mM MgSO4. Warm and dry four LB/MgSO4 agar plate 
(90-mm size) as explained above. 
2.  The following dilutions of the lysate (library) were prepared: Onto 1x lambda dilution 
buffer, 10 µl of the library lysate (dilution 1= 1:100) was pipeted, 10 µl of dilution 1 was 
transferred into a second tube containing 1mL of 1x lambda dilution buffer (Dilution 2 = 
1:10.000). Using XL1-Blue overnight culture, obtained from the last step, and phage dilution 
2, four tubes were prepared. Table 9 exhibits the contents of the four tubes. The tubes were 
incubated in 37 °C water bath for 15 min, 3 ml of melted (45 °C) LB/MgSO4 top agar were 
added to each of the four tubes, mixed well and poured the contents from each tube onto 
separate LB/MgSO4 agar plates (The plates were swirled quickly as mentioned above). 
3. The plates were cooled at room temperature for 10 min, incubated at 37 °C (inverted 
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position) for at least 7 hours. After the growing of the plaques, they were counted and the titer 
was calculated according to the equation in (Paragraph 7.10). A titer of 2x 1010 pfu/ml was 
obtained. The library was stored in 4 °C and was ready for the screening. 
 
Table 9: Plating dilutions for titration of an amplified library. 
1x Lmbda Tube 1x Lambda dilution 
buffer 
Bacterial overnight 
culture 
Phage Dilution2 
1 
2 
3 
4 (Control) 
100 µl 
100 µl 
100 µl 
100 µl 
200 µl 
200 µl 
200 µl 
200 µl 
5 µl 
10 µl 
20  µl 
0 µl 
8. Immunoscreening of cDNA expression library using MDS Sera 
Sera from 10 MDS patients from Department of Hematology, Oncology and Clinical 
Immunology, Düsseldorf University Hospital (Düsseldorf, Germany) were used to screen 
human fetal liver cDNA library and cDNA library from normal CD34+ cells, using the 
SEREX approach as described above (Paragraph 1). First, each serum was diluted at 1/10 
with PBS, pooled and saved at 4°C. The serum pool was screened for antibodies against any 
products in both libraries. About 1x106 clones from each library were screened. 
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VI. Results 
1. Screening with MDS sera 
No reaction could be found by MDS sera neither by using fetal liver cDNA library nor by 
cDNA isolated from a normal individual CD34+. Similarly, the MDS sera did not react with 
the gene products isolated with PNH sera.  
2. Sequence analysis of defined antigens 
The SEREX approach was applied to identify antibodies against auto-antigens using the sera 
of patients with PNH. By screening more than 1 x 106 phage plaques from a human fetal liver 
cDNA library with 1/100 diluted sera from 10 PNH patients, the products of two genes were 
identified (Figure 24). Lineage-specific expression was determined by searching the National 
Center for Biotechnology Information (NCBI) UniGene database 
(http://www.ncbi.nlm.nih.gov/UniGene/):   
 
Figure 24: Positive signals using the SEREX approach. 
2.1. MPHOSPH1 
The first antigen was M-phase phosphoprotein 1(MPHOSPH1) (Termed also: kinesin family 
member 20B or KIF20B), which is a member of a set of mitotic phosphoproteins specifically 
recognized by the MPM2 antibody at the G2/M transition. MPHOSPH1 is a 225-kd protein, 
previously known as a slow plus-end-directed kinesin-related protein (KRP) that plays critical 
roles in cytokinesis (MatsumotoTaniura et al, 1996b). It has a specific pattern of localization 
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and expression during the cell cycle, being mostly nuclear in interphase cells with a sharp 
increase in expression in G2, and diffuse in metaphase cells, with subsequent association to the 
central spindle and the midbody at the end of mitosis. MPHOSPH 1 is a novel KRP whose 
activity is required for proper progression of cytokinesis in human cells. Moreover, using 
immunoblots analysis of MPHOSPH 1 distribution in various human tissues, it had been 
demonstrated that there is no expression of the protein by adult liver tissue (Abaza et al, 
2003b).  
2.2. Desmoplakin 
The second antigen was encoded by the desmoplakin gene which encode a 240 kd protein 
associated with desmosomes. Desmosomes are intercellular junctions that tightly link adjacent 
cells. Desmoplakin is an obligate component of functional desmosomes that anchors 
intermediate filaments to desmosomal plaques (Figure 25). The N-terminus of desmoplakin is 
required for localization to the desmosome and interacts with the N-terminal region of 
plakophilin 1 and plakoglobin. The C-terminus of desmoplakin binds with intermediate 
filaments. In the mid-region of desmoplakin, a coiled-coiled rod domain is responsible for 
homodimerization. Mutations in this gene are the cause of several cardiomyopathies and 
keratodermas as well as the autoimmune disease paraneoplastic pemphigus (Jiao & Bystryn, 
1998b). There is no sufficient information about the tissue expression of desmoplakin, but it is 
known that desmosomes are major sites of intercellular contact found in a variety of cells such 
as epithelial cells, cardiac myocytes, arachnoidal cells of meanings, and dendritic cells of 
germinal centers in lymph nodes (Virata et al, 1992).  
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Figure 25: Cell adhesion in desmosomes. On the cytoplasmic side of the plasma membrane, there 
are two dense structures called the Outer Dense Plaque (ODP) and the Inner Dense Plaque (IDP). 
These are spanned by the desmoplakin protein. The Outer Dense Plaque is where the cytoplasmic 
domains of the cadherins attach to desmoplakin via plakoglobin and plakophillin. The Inner Dense 
Plaque is where desmoplakin attaches to the intermediate filaments of the cell. 
3. Serological analysis of SEREX-defined antigens 
The isolated clones were used to screen for antibodies in the sera of patients with PNH and 
the healthy donors. Three and four of the 10 PNH sera exhibit a positive reaction against 
MPHOSPH1 and desmoplakin, respectively. 
In PNH sera 1, 5 and 9 a positive reaction against MPHOSPH1 was detected, and in PNH sera 
5, 6, 7 and 10 against desmoplakin. Only in one healthy serum number 6 a positive reaction 
against desmoplakin was found. No reaction against either clone was found in any of aplastic 
anemia sera. The results of the screening were summarized in table 10. 
Table 10: Summary of antibody screening.  
 MPHOSPH 1 Desmoplakin 
PNH sera (10) 3 (30%) 4 (40%) 
Aplastic anemia (5) No reaction No reaction 
Control sera  (20) No reaction 1 (5%) 
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Using PBS, dilution series were made for each of sera that exhibited reaction against 
desmoplakin and/ or MPHOSPH1 (1/10, 1/102, 1/103, 1/104, 1/105 and 1/106) and the reaction 
against both of the clones was tested. Even with dilution factor 1/105, the positive reactions 
against MPHOSPH1 were identified in PNH sera numbers 1, 5 and 9. In PNH sera 5, 6, 7 and 
10 a positive reaction against desmoplakin were detected. The positive reaction in control 
serum number 6 against desmoplakin disappeared by diluting the serum at a factor 1/103. 
4. Detection of IgG antibodies against desmoplakin and 
MPHOSPH1 by ELISA and Western blot analysis 
In order to determine the titers of antibodies against the two gene products in the sera of 
patients with PNH, aplastic anemia and healthy controls, sera were tested for reactivity 
against desmoplakin and MPHOSPH1 by ELISA. A serum was considered positive in the 
MPHOSPH1 ELISA if its absorbance value exceeded the mean absorbance value of sera from 
healthy donors by three standard deviations. The results of ELISA for MPHOSPH1 are 
depicted in (Figure 26). 
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Figure 26: ELISA results of all sera against MPHOSPH1. With each of PNH sera number 1, 5 and 
9 the optic density was higher than the medium levels of healthy donor + three times the standard 
deviation. With all sera from aplastic anemia patients and healthy donors, the density was lower than 
Med+3SD.  
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Desmoplakin reactivity was detected in four of the 10 PNH sera, but in none of the aplastic 
anemia sera. A positive reaction against desmoplakin was detected in one normal serum, and 
the OD600 of all positive PNH Sera (OD = 1.22 ± 0.07) was significantly higher than that of 
the normal serum (OD = 0.186 ± 0.09). Figure 27 presents the ELISA results of 10 PNH sera, 
20 healthy donors and 5 aplastic anemia sera against Desmoplakin.  
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Figure 27: ELISA results of all sera against desmoplakin. With each of PNH sera number 5, 
6, 7 and 10, the optic density was higher than the medium levels of healthy donor + three times the 
standard deviation. With all sera from aplastic anemia patients and healthy donors, the density was 
lower than Med+3SD. 
5. Expression of desmoplakin and MPHOSPH1 can be identified 
by CD34+ cells 
The expression of desmoplakin and MPHOSPH1 genes by PCR was analyzed using cDNAs 
derived from testis and CD34+ cells from one PNH patient and one healthy control. GAPDH 
was used as housekeeping gene. The gel electrophoresis of the PCR products is shown in 
(Figure 28). Both desmoplakin and MPHOSPH1 were expressed in CD34+ cells of the PNH 
patient and normal individuals. 
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Figure 28: Gel electrophoresis analysis for cDNA from CD34+ cells. A. Desmoplakin, B. 
MPHOSPH1, C. GAPDH. 1: Negative control, 2: Testis cDNA, 3: Normal CD34+, 4: PNH CD34+. 
The expression of Desmoplakin by normal (A3) and PNH patient (A4) could be identified. The 
expression of MPHOSPH1 also by normal (B3) and PNH (B4) patient is clear. 
6. Epitope mapping 
Using ELISA technique, the reactions of PNH sera against the DNA fragments of 
desmoplakin and MPHOSPH1 were tested. The reaction was considered positive if the 
absorbance value exceeded the mean absorbance value of that of healthy sera by three 
standard deviations. Positive reactivity against the epitopes number three and four (desmo-3 
and desmo-4) for desmoplakin were documented in all PNH sera (5, 6, 7 and 10), that means 
that the epitope is the overlapping region, corresponding to aa's 1377 to 1387. The results of 
ELISA test are depicted in (Figure 29).  
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Figure 29: Elisa results of PNH sera against desmoplakin epitopes. PNH sera number 5, 6, 
7 and 10 show reactivity against desmo-3 and desmo-4 
 
Figure 30: Elisa results of PNH sera against MPHOSPH1 epitopes. PNH sera number 1, 5 
and 9 show reactivity against MPHOSPH1epitope number 1. 
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For MPHOSPH1, positive reactivity in PNH sera numbers 1, 5 and 9 were demonstrated 
against epitopes number 1 corresponding to aa's 204 to 321. The results are depicted in 
(Figure 30). The sequences of desmoplakin and MPHOSPH1 epitopes are shown in (Figure 
31). 
A.  
HQLTMQKEED 
B. 
SHSIFTVKILQIEDSEMSRVIRVSELSLCDLAGSERTMKTQNEGERLRETGNINTSLL
TLGKCINVLKNSEKSKFQQHVPFRESKLTHYFQ 
 
Figure 31: Sequence of the epitopes. (A) Desmoplakin epitope. (B) ) MPHOSPH1 Epitope. 
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VII. Discussion  
Clonal expansion in PNH  
PNH is a unique disorder characterized by the expansion of an abnormal clone or small 
number of clones, which replaces almost the entire hematopoietic stem cell pool. The 
pathophysiology leading to the expansion of GPI-deficient clones within the bone marrow of 
PNH or PNH/aplasia patients is still a matter of controversial discussions (Dunn et al, 1999). 
PNH clones do not exhibit a “malignant” characteristic, because PIG-A mutant clones occur 
at low levels in normal individuals without expanding or competing with normal 
hematopoietic cells (Araten et al, 2001). However, in PNH patients, clonal expansion can lead 
to a complete replacement of almost the entire hematopoietic stem cell pool in PNH patients. 
It was proposed that besides PIG-A mutations a second event enables the expansion of PNH 
clone over the residual normal hematopoietic cells (Inoue et al, 2006b). Genetic instability 
was identified in GPI-deficient cells present in PNH, which is also observed in related 
diseases with defined genetic aberrations such as MDS (Purow et al, 1999;Hattori et al, 
1997). Such additional genetic alterations might affect the cellular activation, proliferation 
and differentiation program, which might be responsible for an altered growth behavior of 
GPI-deficient cells leading to clonal expansion in PNH. The most striking support for the 
hypothesis on additional genetic alterations within the GPI-deficient clone has been published 
In 1996. A chromosomal alteration in PNH clone has been documented in a Japanese patient 
with aplastic anemia who developed clinical evidence of PNH approximately 10 months after 
treatment (Nishimura et al, 1996). Only the PIG-A mutant cells (but not the GPI normal cells) 
were found to exhibit the chromosomal abnormality consisting of an insertion of a fragment 
derived from the long arm of one chromosome 12 into the long arm of the other chromosome 
12; 46,XX, t(12;12)(q13;q15). Rearrangement of chromosome 12 was also documented in 2 
patients with PNH (Inoue et al, 2006b). In both cases, der(12) had a break within the 3′ 
untranslated region of HMGA2, the architectural transcription factor gene deregulated in 
many benign mesenchymal tumors, that caused ectopic expression of HMGA2 in the bone 
marrow (Grosschedl et al, 1994;Reeves, 2001). The ectopic expression in both patients 
appeared to be a consequence of gain-of-function mutational events caused by disruption of 
the 3′ UTR shown to contain elements that negatively regulate HMGA2 transcription 
(Borrmann et al, 2001). However, the study neither established the sequence of events, which 
causes the clonal outgrowth of the double mutant cells nor presented an explanation how the 
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aberrant expression of HMGA2 works with mutant PIGA to generate the proliferative 
phenotype.  
Clonal immuno-selection in PNH 
The frequent appearance of expanded GPI-deficient bone marrow cells in aplastic anemia 
patients has led to the hypothesis that GPI-deficient cells would escape the suppressive action 
of the immune system. This theory is further supported by the observation that in some PNH 
patients more than one GPI-deficient clone is present (Bessler et al, 1994d;Nafa et al, 1995). 
Whether a single PNH clone remains dominant or minor clones become dominant is still 
unclear. Furthermore, it is unknown how many hematopoietic stem cells (HSCs) sustain 
hematopoiesis and how long a single HSC can support hematopoiesis (Dunn et al, 1996). The 
relapse of PNH found in some patients after bone marrow transplantation (BMT) is associated 
with the appearance of new clones and not only the persistence of the original clones, which 
supports the concept that BM environment may create selective conditions favoring the 
expansion of PNH clones (Nafa et al, 1998).  
In addition, the pathogenetic link between AA and PNH is intricate, but too apparent to be 
accidental. Previous studies indicated that circulating blood cells with a deficiency of GPI-
anchored proteins could be detected in about 30–50% of the peripheral blood and bone 
marrow cells of some aplastic anemia patients (Kawaguchi et al, 1999;Schubert et al, 1994). 
This observation has led to the suggestion that normal hematopoietic stem cells might be 
damaged by the immunological mechanism. Whereas, the GPI-deficient cells are not attacked 
and therefore will grow out the damaged bone marrow environment. An immune 
selection/immune escape theory was previously proposed by Luzzatto's group (Bessler et al, 
1994a). According to this theory, autoimmunity in AA is directed against either the GPI-
anchor or a GPI-linked protein, PNH cells being spared, which expand and dominate the 
entire bone marrow. Luzzatto's idea implies the outgrowth of a dysregulated clone of 
immunocytes against GPI-linked proteins or their surface anchor. PNH clone(s) would 
thereby assume a growth advantage leading to their expansion in the aplastic marrow. The 
skewed T-cell repertoire in PNH patients is interpreted as the presence of specific T cell 
clones that recognize the GPI-anchor itself (Karadimitris et al, 2000;Karadimitris & Luzzatto, 
2001b). T cells require additional signals besides that generated by the T cell receptor (TCR) 
complex to respond to antigens. Moreover, the interactions between co-stimulatory ligands 
and their receptors are critical for activation of T lymphocytes, prevention of tolerance and 
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development of T cell-dependent immunity (Kroczek et al, 2004). Therefore, by searching for 
the target antigen(s) of T cells in PNH, the concept that this target antigen(s) could be other 
than GPI-anchor antigen, and a GPI-anchor protein(s) just works as co-stimulatory factor for 
the activated T cells, should be considered (Murakami et al, 2002d).    
Because the expression of GPI anchor is not restricted to HSC, an autoimmune attack against 
the GPI anchor would probably cause fatal ubiquitous tissue damage. Moreover, the concept 
that the GPI anchor serves as the target of immune system, means that PNH cells lacking the 
GPI-anchor are more resistant to T cell attack than normal (GPI+) cells. However GPI-
deficient cells exhibit the same susceptibility to the cytotoxic action of allogeneic T-cells as 
normal cells (Karadimitris & Luzzatto, 2001a). Alternatively, it has been proposed that the 
autoimmune attack restricted to HSC could be associated with an expansion of cytotoxic 
T/NK cells recognizing GPI-anchor structures in the context of CD1d molecules. Such clones 
were found in other autoimmune diseases, but not in PNH or AA patients so far. An 
alternative explanation could be that GPI-linked surface proteins such as ULBP’s 
(cytomegalovirus glycoprotein UL16 binding proteins) might directly interfere with activating 
receptors (NKG2D) on NK cells (Pende et al, 2001). However, the expression pattern of these 
molecules is unknown to date. 
It has been also suggested that GPI-deficiency itself leads to an increased resistance to 
apoptosis (Brodsky et al, 1997).  Moreover, it was documented that granulocytes not only 
from PNH, but also from AA and MDS patients are relatively resistant to apoptosis (Nagakura 
et al, 2002b). If GPI-deficient cells would exhibit a resistance to apoptosis only because of the 
absence of GPI-linked surface molecules, clonal dominance of the GPI-deficient clone would 
be found also in AA and MDS. However, such a resistance strictly due to GPI-deficiency 
could not be reproduced by other groups (Ware et al, 1998;Bastisch et al, 2000a). Therefore, 
it is suspected that resistance to apoptosis observed in GPI-deficient cells of PNH patients 
would be a result of changes distinct from the deficient surface expression of GPI-linked 
proteins. 
Based on all observations mentioned above, the immune selection/immune escape theory can 
give a better explanation of both the GPI deficient cells documented in aplastic anemia and 
the clonal dominance in PNH. However, the target antigens of such immune attack have to be 
identified in order to understand the mechanism of this selection. The alternative hypothesis, 
as mentioned above, includes internal alterations within clonal cells such as mutations in 
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genes regulating cell proliferation and apoptosis. A combination between both theories might 
provide a basis for more understanding of the pathophysiology of PNH, so that; the 
development of PNH will need three steps, elucidated in (Figure 32): 
 
Figure 32: Sequence of events necessary for development of PNH. Modified according to (Inoue et 
al, 2006b) 
In the first step, a somatic mutation of PIG-A gene on the X chromosome occurs. The second 
step will be the immune attack directed against normal HSC, which spares the GPI – cells 
because either these cells are not expressing the target antigens of the immune system or 
because the deficiency of some GPI-anchor proteins makes these cells less susceptible to be 
killed by cytotoxic T cells. This hypothesis would be supported by the observation that in the 
context of aplastic anemia, the proportion of GPI-deficient cells expands to a certain extent, 
but in most cases does not give rise to a predominant clone within the bone marrow. In the 
third step, an additional mutation provides the internal growth advantage to the selected GPI – 
cells in order to expand and fill the vacuum caused by the immune attack of normal cells. The 
sequence of events in clonal expansion could be explained more adequately by a combination 
of both opposed hypotheses.  
This hypothesis implies the possibility of autoantibody production by PNH patients. A defect 
in the immune system in the second step leads to the production of antibodies and 
consequently an immune attack directed against special antigens. The identification of these 
antigens could help to understand the exact mechanism of the immune selection in PNH. 
Moreover, the identification of a humoral immune response to the target antigens may imply a 
pathologic T-cell immune response to the same antigens. According to the clonal expansion in 
the third step, the immune system recognizes the genetic alterations in the target cells and 
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produces antibodies against the modified antigens. Although these antibodies might play no 
role in the pathophysiology of the disease, the identification of these antibodies will prove the 
occurrence of such alterations in the target cells.      
In order to identify the target antigen, the SEREX approach was applied to screen a human 
fetal liver cDNA library, because fetal liver is known to be highly enriched for CD34+ cells. 
Using sera from 10 PNH patients, two auto-immunogenic structures were found: MPHOSPH1 
(known also as kinesin family member 20B or KIF20B) and desmoplakin (DSP). 
M- Phase phosphoprotein 1 (MPHOSPH1) 
The human M-phase phosphoprotein 1 (MPHOSPH1) was originally identified through a 
screening of a subset of proteins specifically phosphorylated at the G2/M transition 
(MatsumotoTaniura et al, 1996a). MPHOSPH1 is a 225 KD protein, characterized as a plus-
end-directed kinesin-related protein. Recombinant MPHOSPH1 exhibits in vitro microtubule-
binding and microtubule-bundling properties as well as microtubule-stimulated ATPase 
activity. Using polarity-marked microtubules it was found that MPHOSPH1 is a slow 
molecular motor that moves toward the microtubule plus-end at a 0.07 µm/s speed. In cycling 
cells, MPHOSPH1 localizes mainly at the nuclei in interphase. During mitosis, MPHOSPH1 
is diffused throughout the cytoplasm in metaphase and subsequently localizes to the midzone 
to further concentrate on the midbody. MPHOSPH1 suppression by RNA interference induces 
failure of cell division late in cytokinesis. Autoantibodies against MPHOSPH1 were found in 
40% of patients of idiopathic ataxia, which is known to be an autoimmune disease (Fritzler et 
al, 2000). In this study, IgG antibodies against MPHOSPH1 were found in 3 out of 10 PNH 
patients (30%). No antibody response against MPHOSPH1 could be detected in 10 MDS 
patients, 5 aplastic anemia patients, or 20 normal individuals. Occurrence of anti-MPHOSPH1 
Abs in PNH patients and none of MDS or aplastic anemia patients supports a specific 
association of these antibodies with PNH. However, it should be mentioned that these 
antibodies were documented in a part and not all PNH patients included in the study.    
Moreover, the expression of MPHOSPH1 in CD34+ cells (from PNH and normal individual) 
was demonstrated in the study, which gives more support to the theory that MPHOSPH1 
could be a target antigen of the immune attack in PNH. In addition to their expression in 
human hematopoietic cells, MPHOSPH1 transcripts were previously found in human Kidney, 
testis, and brain (Abaza et al, 2003a).  
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The sequencing of MPHOSPH1 DNA from PNH CD34+ cells and normal CD34+ cells 
revealed no differences in the sequences, however posttranslational modifications could not 
be ruled out. Although, the nuclear localization of MPHOSPH1 protein during the cell cycle 
may undermine the theory that anti-MPHOSPH1 antibodies affect the function and viability 
of hematopoietic cells in PNH patients. It was documented in other studies (Bastisch et al, 
2000b) that anti-MPHOSPH1 antibodies occur in a high frequency with other autoimmune 
diseases (40 % of idiopathic ataxia patients) and play a role in the pathophysiology of this 
autoimmune disease. Furthermore, it was documented that the immune reaction, for example 
in a solid tumor, can be directed against intracellular antigens (Yoon & Jun, 1999b). Thus, 
MPHOSPH1 could be a candidate antigen, which evokes the reaction of immune system 
against hematopoietic stem cells, especially because the expression of the protein in CD34+ 
cells was documented in this study.  
Desmoplakin 
Desmoplakin is a (240 KD) protein associated with desmosomes. Desmosomes are 
intercellular junctions that tightly link adjacent cells and desmoplakin is an obligate 
component of functional desmosomes that anchor intermediate filaments to desmosomal 
plaques. The N-terminus of desmoplakin is required for localization to the desmosome and 
interacts with the N-terminal region of plakophilin 1 and plakoglobin. The C-terminus of 
desmoplakin binds to intermediate filaments. In the mid-region of desmoplakin, a coiled-
coiled rod domain is responsible for homodimerization (Arnemann et al, 1991). 
Autoantibodies against desmoplakin were found not only in patients with paraneoplastic 
pemphigus (Anhalt et al, 1990), but also in patients with non-neoplastic pemphigus (Jiao & 
Bystryn, 1998a;MatsumotoTaniura et al, 1996a) which means that, the production of these 
antibodies is not necessarily tumor-related. Although the roles of anti-desmoplakin antibodies 
in the pathophysiology of paraneoplastic pemphigus are not known, their existence is one of 
the diagnostic criteria for the disease (Oursler et al, 1992). Serological activity against 
desmoplakin was demonstrated in 4 out of 10 classic PNH patients (40%), but none of the 10 
MDS patients or 5 aplastic anemia patients exhibited reactivity against desmoplakin. In a 
1/100 diluted normal serum, a weak reactivity against desmoplakin could be identified; 
however the reactivity disappeared after dilution of the serum up to 1/ 1000. Moreover, 
determination of anti-desmoplakin antibodies with ELISA indicated that the OD of all 
positive PNH Sera (OD = 1.22 ± 0.07) was significantly higher than that of the normal serum 
(OD = 0.186 ± 0.09). The expression of desmoplakin was demonstrated in CD34+ cells from 
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both normal and PNH bone marrow. The sequences of desmoplakin cDNA from the patient 
and the control were identical. Although the localization of desmoplakin is intracellular and 
the expression of the protein is ubiquitous in the body tissues, the role of anti-desmoplakin 
antibodies in the pathophysiology of auotimmune disease (e.g. pemphigus) could not be 
determined. The serological reactivities against MPHOSPH1 and desmoplakin were 
documented in patients who did not have a history of transfusion (patients number 1 and 7 
exhibited reactivity against MPHOSPH1 and desmoplakin respectively) and other patients 
who had received transfusion (patient number 5), therefore it is unlikely that the patients 
developed antibodies because of the blood transfusion.  
The results of the study support the hypothesis that humoral immune responses to antigens on 
hematopoietic cells are involved in the pathophysiology of PNH. The finding of high-titered 
IgG responses found in PNH patients implies cognate T-cells help. In an approach of “reverse 
T-cell immunology”, it is now possible to determine the epitopes of MPHOSPH1 and 
desmoplakin that are presented to CD4+ and CD8+ cells in the context of MHC-II and MHC-I 
epitopes respectively. The elucidation of these T-cell responses will give us more insight into 
the role of anti-desmoplakin and anti-MPHOSPH1 in the pathophysiology of PNH. Analysis 
of larger numbers of patients with PNH will show whether anti-MPHOSPH1 and anti-
desmoplakin antibodies can be used as diagnostic and/or prognostic markers of PNH. While 
MPHOSPH1 and desmoplakin are expressed by CD34+ cells in both PNH patients and 
healthy individuals, the conditions that render the two structures immunogenic in patients 
with PNH, but not in healthy controls, must still be determined. According to one model, the 
presentation of non-altered molecules in the context of “danger” breaks down auto-tolerance 
(Matzinger, 2002). Alternatively, mutations of the two antigens in the CD34+ cells of PNH 
patients, or posttranslational modifications like differential glycosylations or phosphorylations 
could render desmoplakin and MPHOSPH1 auto-immunogenic in PNH patients. The exact 
role of the isolated antigens in the pathophysiology of PNH has not yet been definitely 
demonstrated. So far, it has not yet been completely excluded that these antibodies may arise 
by chance. However, the titers obtained from the patients compared to the controls are quite 
striking. In addition, it might be argued that the antibodies are not consistently present in all 
PNH patients. So far, it is not yet clear what the immunological mechanism of clonal 
expansion consists of. It may be that the immunological basis of such an immunological 
recognition is quite heterogeneous and consists of multiple antigen recognition mechanisms. 
It is of course very challenging to assume a pathophysiological role for the detected antigens. 
On the other hand, in the case of autoimmunity, target structures would be of interest as was 
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shown for patients with aplastic anemia. In autoimmune disorders involving solid tissues, 
proteins likely to elicit autoimmune reactions are `cryptic', i.e. intracellular, rather than 
expressed at the surface, and presented to the immune system upon disintegration of the cell 
(Atkins et al, 2000;Yoon & Jun, 1999a).  
Finally, such antigens detected by autoantibodies could serve as a guide for deregulated genes 
in affected cells. The specificity of desmoplakin and MPHOSPH1 as auto antigens for PNH 
must be further investigated by studying another group of autoimmune diseases. Until then, 
desmoplakin and MPHOSPH1 remain the most promising proteins in the immuno-
pathophysiology of PNH. 
Immune response in MDS patients 
Myelodysplastic syndromes (MDS) are a heterogeneous group of acquired neoplastic 
disorders of multipotent hematopoietic stem cells characterized by increasing bone marrow 
failure with quantitative and qualitative abnormalities of all three myeloid cell lines. A 
hallmark of the disease is an active but ineffective hematopoiesis leading to peripheral 
pancytopenia. The pathophysiology of bone marrow failure by MDS patients, which causes 
blood transfusion dependence and neutropenic infection, is still unknown. MDS share some of 
the features of aplastic anemia, a disease with an established autoimmune pathogenesis, which 
suggests a role of the immune system in the pathophysiology of bone marrow failure in MDS 
similar to that in aplastic anemia. Many investigations focused on the immune-mediated bone 
marrow failure especially in the early stages of MDS as in refractory anemia RA and 
refractory anemia with ringed sideroblasts RARS, (Barrett et al, 2000). Cases of MDS 
showed also response to immune suppressive therapy (IST) with anti-thymocyte globulin, 
which is known to be effective in aplastic anemia. This therapy is associated with loss of 
lymphocyte-mediated inhibition of granulocyte-macrophage colony-forming units and 
alterations in T-cell receptor Vβ profiles (Molldrem et al, 1998). Different antibodies were 
found in bone marrow culture of many MDS patients, especially in RA patients, but neither 
the role of these antibodies in cytopenia nor the target antigens of these antibodies could be 
identified. Many clinical observations and laboratory studies suggest that the immune system 
might mediate bone marrow failure in some MDS patients. In one respect, the suggestion 
depended on the accumulating evidence of immunologic abnormalities in MDS, including, 
high levels of tumor necrosis factor (TNF, Gersuk et al, 1998), differentially regulated FLIP 
(FAS-associated death domain-like interleukin [IL]-1 converting enzyme, Kochenderfer et al, 
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2002a), presence of cytotoxic T cells and clonality of T-cell clones (Maciejewski et al, 2002). 
On the other hand, the conclusion that the immune system may mediate bone marrow failure 
in some MDS patients is underscored by the association between MDS and many autoimmune 
diseases (Hamblin, 1987): MDS is sometimes seen in conjunction with Reynaud’s syndrome, 
rheumatoid arthritis, and polymyalgia rheumatica. Furthermore, MDS is associated with 
aplastic anemia: patients with AA can develop MDS and have overlapping syndromes of 
severe aplastic anemia with features of MDS, which frequently give rise to diagnostic 
confusion. Tichelli et al, were the first to describe inhibition of erythroid colony growth by 
autologous T cells in some patients with MDS (Tichelli et al, 1988). After that, many studies 
demonstrated that treatment with anti-lymphocyte globulin (ATG) abrogates the T-cell 
mediated suppression of granulocyte colony growth in MDS patients, which improves 
marrow function and lessens transfusion dependence (Barrett & Sloand, 2009). These findings 
strongly support T-cell mediated marrow suppression as the cause of cytopenia in about 20–
30% of MDS patients.  
Despite all immunological findings in MDS patients (which may indicate an alteration in 
regulatory mechanisms of B lymphocytes) (Okada et al, 1999), the exact role of these 
abnormal immune reactions in the etiopathogenesis of MDS is not known. It was suggested 
that an increase in the number of monocytes, which is frequent in all types of MDS, explains 
the alteration, for example, monocytes secrete IL-1 that regulates the growth and 
differentiation of B lymphocytes (Lipsky et al, 1983). On the other hand, many patients with 
MDS receive multiple transfusions and a significant percentage of them become 
alloimmunized against RBC antigens (Sokol et al, 1989). Moreover, in some MDS patients, 
there is a high incidence of red cell antibodies without clinical or laboratory alteration in 
hemolysis (Novaretti et al, 2001). In this study, the serological response against hematopoietic 
stem cells in a cohort of MDS patients was tested in the same way as the PNH patients 
included in the study. Ten patients with MDS were screened using the SEREX approach with 
a human fetal liver cDNA library and a cDNA library from CD34+ cells of a normal 
individual. No reaction, neither by MDS pool nor by each individual serum could be 
identified using both the human fetal liver cDNA library and the normal CD34+ cells cDNA 
library. My findings support the suggestion that PNH and MDS are separate diseases and not 
one syndrome. While no serological reactions could be identified in MDS sera against 
hematopoietic cells, such reactions were documented by the screening of PNH sera, which 
postulates an immune reactivity in the pathophysiology of some PNH patients in form of 
antibody response against MPHOSPH1 and/or desmoplakin. Further studies are required in 
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order to determine the mechanism by which desmoplakin and MPHOSPH1 evoke the immune 
system in a larger number of PNH patients. Analysis of the structure of both proteins in 
CD34+ cells from PNH patients, the type of HLA on HSPCs that presents the antigens to the 
T cells, and the ability of the peptides derived from both antigens to activate cytotoxic T cells 
should explain the role of these antigens in the pathophysiology of PNH. Moreover, 
determination of changes in the level of antibodies against both antigens in sera of PNH 
patients, during the treatment and after bone marrow transplantation may give more 
information about the usefulness of using these antibodies as diagnostic and/or prognostic 
markers in PNH.    
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